var title_f33_11_33968="Levofloxacin: Pediatric drug information";
var content_f33_11_33968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5299?source=see_link\">",
"       Levofloxacin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/13/23768?source=see_link\">",
"       Levofloxacin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12549 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33968=[""].join("\n");
var outline_f33_11_33968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/13/23768?source=related_link\">",
"      Levofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33969="Calamine lotion: Drug information";
var content_f33_11_33969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calamine lotion: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/34/38433?source=see_link\">",
"    see \"Calamine lotion: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12607294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12607284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin protectant: Topical: Apply to affected area as often as needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12607283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/34/38433?source=see_link\">",
"      see \"Calamine lotion: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12617674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical: 8% (118 mL, 177 mL, 240 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12607330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12607297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to use. Apply to clean, dry skin; avoid contact with eyes and mucous membranes; do not use on open wounds or burns.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F239483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Employed primarily as an astringent, protectant, and soothing agent for conditions such as poison ivy, poison oak, poison sumac, sunburn, insect bites, or minor skin irritations",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F239485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F239476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): For external use only; avoid contact with eyes and mucous membranes. Discontinue use and contact healthcare provider if needed for &gt;7 days or if condition worsens.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12757380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16451 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33969=[""].join("\n");
var outline_f33_11_33969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607294\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607284\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607283\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617674\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607330\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607297\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239485\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239476\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298924\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12757380\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/34/38433?source=related_link\">",
"      Calamine lotion: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33970="Cryocrit";
var content_f33_11_33970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryocrit analysis of cryoglobulin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cryocrit in a Wintrobe tube from a patient with a monoclonal gammopathy. One cryocrit was 25 percent and the other 35 percent. The patient's serum was refrigerated at 4&deg;C for 72 hours and was then centrifuged to determine the proportion forming a cryoprecipitate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33970=[""].join("\n");
var outline_f33_11_33970=null;
var title_f33_11_33971="T4 pancreatic cancer EUS";
var content_f33_11_33971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic cancer staging with endoscopic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound view of pancreatic cancer (MASS) that can be seen invading into the portal vein (PV) with loss of the vascular interface (arrow). This tumor is stage T4.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank G Gress, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33971=[""].join("\n");
var outline_f33_11_33971=null;
var title_f33_11_33972="Elevated papules";
var content_f33_11_33972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Higher power view demonstrates the elevated papules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol 2004; 19:583. Copyright &copy; 2004 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33972=[""].join("\n");
var outline_f33_11_33972=null;
var title_f33_11_33973="Intravascular lymphoma brain biopsy";
var content_f33_11_33973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Intravascular lymphoma brain biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain biopsy of a patient with intravascular lymphoma demonstrates CD20 positive neoplastic lymphoid cells lodged within in the capillaries and post-capillary venules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by Nika Aljinovic, MD and German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33973=[""].join("\n");
var outline_f33_11_33973=null;
var title_f33_11_33974="Prenatal ultrasound images of normal three vessel umbilical cord";
var content_f33_11_33974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound images of normal three vessel umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Transverse view of a normal umbilical cord shows the characteristic \"Mickey mouse\" appearance with two arteries (a) and one vein (v) surrounded by the Wharton's jelly. Upper panel, conventional two-dimensional ultrasound. Middle panel, color Doppler ultrasound shows blood flow in different directions (arteries in red, vein in blue). Lower panel, power Doppler ultrasound highlights the presence of angle-independent blood flow signals.",
"    <br>",
"     (Panel B) Longitudinal view of a three-vessel umbilical cord shows the arteries (a) looping around the vein (v). Upper panel, conventional two-dimensional ultrasound. Lower panel, color Doppler ultrasound (arteries in red, vein in blue).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33974=[""].join("\n");
var outline_f33_11_33974=null;
var title_f33_11_33975="Recombinant human factor VIII: Pediatric drug information";
var content_f33_11_33975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Recombinant human factor VIII: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"    see \"Recombinant human factor VIII: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/32/22020?source=see_link\">",
"    see \"Recombinant human factor VIII: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advate;",
"     </li>",
"     <li>",
"      Helixate&reg; FS;",
"     </li>",
"     <li>",
"      Kogenate&reg; FS;",
"     </li>",
"     <li>",
"      Recombinate;",
"     </li>",
"     <li>",
"      Xyntha&reg;;",
"     </li>",
"     <li>",
"      Xyntha&reg; Solofuse&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advate;",
"     </li>",
"     <li>",
"      Helixate&reg; FS;",
"     </li>",
"     <li>",
"      Kogenate&reg; FS;",
"     </li>",
"     <li>",
"      Xyntha&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11432529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"     <b>",
"      Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment;",
"     </b>",
"     for every 1 international unit per kg body weight of rAHF administered, factor VIII level should increase by 2%; calculated dosage should be adjusted to the actual vial size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Formula to calculate dosage required, based on desired increase in factor VIII (% of normal) (",
"     <b>",
"      Note:",
"     </b>",
"     This formula assumes that the patient's baseline AHF level is &lt;1%): International units required = body weight (kg) x 0.5 x desired increase in factor VIII (international units/dL or % of normal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines",
"     </b>",
"     (consult individual product labeling for specific dosage recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage (required peak postinfusion AHF level: 20% to 40%): 10-20 international units/kg; repeat every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved; mild, superficial, or early hemorrhages may respond to a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hemorrhage (required peak post-infusion AHF level: 30% to 60%): 15-30 international units/kg, repeat every 12-24 hours for 3-4 days until pain and disability are resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe/life-threatening hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Helixate&reg; FS, Kogenate&reg; FS (required peak post-infusion AHF level: 80% to 100%): Initial: 40-50 international units/kg; maintenance: 20-25 international units/kg every 8-12 hours until bleeding is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Advate, Recombinate&trade;, ReFacto&reg;, Xyntha&trade; (required peak post-infusion AHF level: 60% to 100%): 30-50 international units/kg; repeat every 8-24 hours until threat is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor surgery (required peak postinfusion AHF level: range: 30% to 80%): 15-40 international units/kg; dose is highly dependent upon procedure and specific product recommendations; for some procedures, a single dose plus oral antifibrinolytic therapy within 1 hour is sufficient; in other procedures, may repeat dose every 12-24 hours until bleeding is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Advate (required peak pre- and postsurgery AHF level: 80% to 120%): 40-60 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Helixate&reg; FS, Kogenate&reg; FS (required peak pre- and postsurgery AHF level: 100%): 50 international units/kg; may repeat every 6-12 hours initially and until healing complete (10-14 days); intensity of regimen is dependent on type of surgery and postoperative care",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recombinate&trade;, ReFacto&reg; (required peak pre- and post-surgery AHF level: 80% to 100%): 40-50 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Xyntha&trade; (required peak pre- and postsurgery AHF level: 60% to 100%): 30-50 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis (may also be given on a regular schedule to prevent bleeding):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Joint bleeding prophylaxis: No pre-existing joint damage: Helixate&reg; FS, Kogenate&reg; FS: 25 international units/kg given every other day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=see_link\">",
"      see \"Recombinant human factor VIII: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adults: I.V.:",
"     <b>",
"      Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment;",
"     </b>",
"     for every 1 international unit per kg body weight of rAHF administered, factor VIII level should increase by 2%; calculated dosage should be adjusted to the actual vial size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Formula to calculate dosage required, based on desired increase in factor VIII (% of normal) (",
"     <b>",
"      Note:",
"     </b>",
"     This formula assumes that the patient's baseline AHF level is &lt;1%): International units required = body weight (kg) x 0.5 x desired increase in factor VIII (international units/dL or % of normal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines",
"     </b>",
"     (consult individual product labeling for specific dosage recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage (required peak postinfusion AHF level: 20% to 40%): 10-20 international units/kg; repeat every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved; mild, superficial, or early hemorrhages may respond to a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hemorrhage (required peak post-infusion AHF level: 30% to 60%): 15-30 international units/kg, repeat every 12-24 hours for 3-4 days until pain and disability are resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe/life-threatening hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Helixate&reg; FS, Kogenate&reg; FS (required peak post-infusion AHF level: 80% to 100%): Initial: 40-50 international units/kg; maintenance: 20-25 international units/kg every 8-12 hours until bleeding is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Advate, Recombinate&trade;, ReFacto&reg;, Xyntha&trade; (required peak post-infusion AHF level: 60% to 100%): 30-50 international units/kg; repeat every 8-24 hours until threat is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor surgery (required peak postinfusion AHF level: range: 30% to 80%): 15-40 international units/kg; dose is highly dependent upon procedure and specific product recommendations; for some procedures, a single dose plus oral antifibrinolytic therapy within 1 hour is sufficient; in other procedures, may repeat dose every 12-24 hours until bleeding is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Advate (required peak pre- and postsurgery AHF level: 80% to 120%): 40-60 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Helixate&reg; FS, Kogenate&reg; FS (required peak pre- and postsurgery AHF level: 100%): 50 international units/kg; may repeat every 6-12 hours initially and until healing complete (10-14 days); intensity of regimen is dependent on type of surgery and postoperative care",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recombinate&trade;, ReFacto&reg; (required peak pre- and post-surgery AHF level: 80% to 100%): 40-50 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Xyntha&trade; (required peak pre- and postsurgery AHF level: 60% to 100%): 30-50 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis (may also be given on a regular schedule to prevent bleeding):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Joint bleeding prophylaxis: Children with no pre-existing joint damage: Helixate&reg; FS, Kogenate&reg; FS: 25 international units/kg given every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advate: 250 units, 500 units, 1000 units, 1500 units, 2000 units, 3000 units, 4000 units [plasma/albumin free; contains mannitol, polysorbate 80, sodium; derived from or manufactured using hamster or mouse protein; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helixate&reg; FS: 250 units, 500 units, 1000 units [contains polysorbate 80, sodium, sucrose 28 mg/vial; derived from or manufactured using hamster or mouse protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helixate&reg; FS: 2000 units, 3000 units [contains polysorbate 80, sodium, sucrose 52 mg/vial; derived from or manufactured using hamster or mouse protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kogenate&reg; FS: 250 units, 500 units, 1000 units [contains polysorbate 80, sodium, sucrose 28 mg/vial; derived from or manufactured using hamster or mouse protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kogenate&reg; FS: 2000 units, 3000 units [contains polysorbate 80, sodium, sucrose 52 mg/vial; derived from or manufactured using hamster or mouse protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recombinate: 250 units, 500 units, 1000 units, 1500 units, 2000 units [contains albumin (human), natural rubber/natural latex in packaging, polysorbate 80, sodium; derived from or manufactured using bovine, hamster or mouse protein; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xyntha&reg;: 250 units, 500 units, 1000 units, 2000 units [albumin free; contains polysorbate 80, sucrose; derived from or manufactured using hamster  protein; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xyntha&reg; Solofuse&trade;: 1000 units, 2000 units, 3000 units [albumin free; contains polysorbate 80, sucrose; derived from or manufactured using hamster protein; dual-chamber syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reconstitution: If refrigerated, the dried concentrate and diluent should be warmed to room temperature before reconstitution; see individual product labeling for specific reconstitution guidelines; gently agitate or rotate vial after adding diluent, do not shake vigorously. Use filter needle provided by manufacturer to draw product into syringe (all products except Xyntha&trade;); do",
"     <b>",
"      not",
"     </b>",
"     refrigerate after reconstitution; administer within 3 hours after reconstitution;",
"     <b>",
"      Note:",
"     </b>",
"     Use plastic syringes, since rAHF may stick to the surface of glass syringes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V. administration only; total dose may be administered over 5-10 minutes; Advate may be administered over &le;5 minutes; Helixate&reg; FS and Kogenate&reg; FS may be administered over 1-15 minutes; maximum rate of infusion (all products): 10 mL/minute; adjust administration rate based on patient response (all products); for Advate, Helixate&reg; FS, Kogenate&reg; FS, and ReFacto&reg;, use sterile administration set provided by manufacturer",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Storage: Store unopened vials under refrigeration 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); avoid freezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advate: May also be stored at room temperature [22&deg;C to 28&deg;C (72&deg;F to 82&deg;F)] for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Helixate&reg; FS, Kogenate&reg; FS, ReFacto&reg;, Xyntha&trade;: May also be stored at room temperature (&le;25&deg;C or 77&deg;F) for up to 3 months. Avoid extreme or prolonged exposure to light during storage (store drug in carton before use). Kogenate&reg; FS: Do not return vials to refrigeration, once removed from refrigeration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recombinate&trade;: May also be stored at room temperature (&le;30&deg;C or 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Antihemophilic Factor (Recombinant) is not indicated for the treatment of von Willebrand disease.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Advate: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in ages 0-16 years and adults); perioperative management of patients with hemophilia A (FDA approved in ages 0-16 years and adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Helixate&reg; FS, Kogenate&reg; FS: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in ages 0-16 and adults); perioperative management of patients with hemophilia A (FDA approved in ages 0-16 years and adults); prophylaxis of joint bleeding and reduction of the risk of joint damage in children with hemophilia A with no pre-existing joint damage (FDA approved in ages 0-16 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Recombinate&trade;, ReFacto&reg;: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in all ages); perioperative management of patients with hemophilia A (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Xyntha&trade;: Prevention and control of hemorrhagic episodes in patients with hemophilia A (FDA approved in adults); perioperative management of patients with hemophilia A (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Has also been used in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6814324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor VIII may be confused with Factor XIII",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, joint swelling, pain in extremity, weakness",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Otic: Ear infection, ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, nasopharyngitis, pharyngolaryngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Catheter thrombosis, catheter infection, factor VIII inhibitor formation, flu-like syndrome, influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening:  Abdominal pain, adenopathy, allergic reactions, anaphylaxis, anemia, angioedema, anorexia, arthralgia, AST increased, chest discomfort, chest pain,  cyanosis, depersonalization, diaphoresis, dyspnea, edema, epistaxis, erythema, facial edema, facial flushing, factor VIII decreased, fatigue, GI hemorrhage, hematoma, hives, hot flashes, hyperhidrosis, hypersensitivity reaction, hyper-/hypotension (slight), infection, laryngeal edema, lethargy, malaise, pallor, paresthesia, restlessness, rhinitis, rigors, shortness of breath, somnolence, tachycardia, tremor, urinary tract infection, vasodilation, venous catheter access complications",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     All products: Hypersensitivity or intolerance to any component (see table)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Advate; Helixate&reg; FS; Kogenate&reg; FS: Hypersensitivity to mouse or hamster protein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recombinate&trade;; ReFacto&reg;: Hypersensitivity to mouse, hamster, or bovine protein",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Antihemophilic Factor (Recombinant) [Factor VIII (Recombinant)] Products",
"     </caption>",
"     <col align=\"left\" width=\"130\">",
"     </col>",
"     <col align=\"left\" width=\"120\">",
"     </col>",
"     <col align=\"left\" width=\"120\">",
"     </col>",
"     <col align=\"left\" width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Product",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Synthesis",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Purification Methods",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Stabilizers and Excipients",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Listed as a stabilizer in the product's package insert.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Advate",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Chinese hamster ovary (CHO) cell line",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Plasma/albumin - free method",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Solvent/detergent virus inactivation",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Column chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Monoclonal antibody immunoaffinity chromatography",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Mannitol",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Trehalose",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Tris",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Glutathione",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; von Willebrand factor (insignificant amounts)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Helixate&reg; FS",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Baby hamster kidney (BHK) cells",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Human plasma protein solution (HPPS) and recombinant insulin in cell culture medium",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Solvent/detergent virus inactivation",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Ion exchange chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Monoclonal antibody immunoaffinity chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Other chromatographic steps",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sucrose",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Glycine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Imidazole",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Tri-n-butyl phosphate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Copper",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Kogenate&reg; FS",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Baby hamster kidney (BHK) cells",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Human plasma protein solution (HPPS) and recombinant insulin in cell culture medium",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Solvent/detergent virus inactivation",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Ion exchange chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Monoclonal antibody immunoaffinity chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Other chromatographic steps",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sucrose",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Glycine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Imidazole",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Tri-n-butyl phosphate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Copper",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Recombinate&trade;",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Chinese hamster ovary (CHO) cell line",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Column chromatography",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Monoclonal antibody immunoaffinity chromatography",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Albumin (human)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polyethylene glycol",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; von Willebrand factor",
"         <sup>",
"          1",
"         </sup>",
"         (insignificant amounts)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         ReFacto&reg;",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Chinese hamster ovary (CHO) cell line",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Human serum albumin and recombinant insulin in cell culture medium",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Chromatography",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sucrose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; L-histadine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Xyntha&trade;",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Recombinant DNA technology",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Chinese hamster ovary (CHO) cell line",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Chromatography",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Solvent/detergent virus inactivation",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Virus nanofiltration",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sodium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Sucrose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; L-histadine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate-80",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical response to recommended doses may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. Formation of factor VIII inhibitors (neutralizing antibodies to AHF recombinant) may occur; antibody formation may occur at any time, but is more common in young children with severe hemophilia during the first years of therapy, or in patients at any age who received little prior therapy with factor VIII; monitor patients appropriately. Although remote, formation of antibodies to mouse, hamster, or bovine protein may occur (products may contain trace amounts of these proteins). Allergic type hypersensitivity reactions, including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Products vary by preparation method (see table). Recombinate&trade; formulation is stabilized using human albumin; Helixate&reg; FS, Kogenate&reg; FS, ReFacto&reg;, and Xyntha&trade; formulations are stabilized using sucrose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinate&trade; contains natural rubber latex (in certain components of the product packaging) which may cause allergic reactions in susceptible individuals; avoid use in patients with allergy to latex. All brands contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Safety and efficacy in pregnant women has not been established. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding; heart rate and blood pressure (before and during I.V. administration); AHF levels prior to and during treatment; monitor for the development of inhibitor antibodies by clinical observations (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma antihemophilic factor level:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal range: 50% to 150%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Level to prevent spontaneous hemorrhage: 5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Required peak post-infusion AHF activity in blood (as % of normal or units/dL plasma):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Early hemarthrosis, muscle bleed, or oral bleed: 20% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     More extensive hemarthrosis, muscle bleed, or hematoma: 30% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Life-threatening bleeds (such as head injury, throat bleed, severe abdominal pain): 80% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor surgery, including tooth extraction: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery: 80% to 100% (pre- and postoperative)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antihemophilic factor (recombinant) has the same biological activity as AHF (factor VIII) derived from human plasma; factor VIII is a protein in normal plasma which is necessary for clot formation and maintenance of hemostasis; factor VIII activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 4-18 years of age (mean age: 12 years): Mean: 10.7 hours (range: 7.8-15.3)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Mean: 11-16 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/32/22020?source=see_link\">",
"      see \"Recombinant human factor VIII: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be given intravenously. Stop taking antihemophilic factor recombinant and notify physician immediately if any of the following signs or symptoms of an allergic (hypersensitivity) reaction occur: Itching, hives, low blood pressure, tightness of the chest, wheezing, or anaphylaxis. Wear identification indicating that you have a hemophilic condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One international unit of rAHF is equal to the factor VIII activity present in 1 mL of fresh pooled human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of rAHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large rAHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abshire TC, Brackmann HH, Scharrer I, et al, &ldquo;Sucrose Formulated Recombinant Human Antihemophilic Factor VIII is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. International Kogenate-FS Study Group,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2000, 83(6):811-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/10896230/pubmed\" id=\"10896230\" target=\"_blank\">",
"        10896230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bray GL, Gomperts ED, Courter S, et al, &ldquo;A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A. The Recombinate Study Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1994, 83(9):2428-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/8167332 /pubmed\" id=\"8167332 \" target=\"_blank\">",
"        8167332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, Butler RB, Farace L, et al, &ldquo;Superior In Vivo Response of Recombinant Factor VIII Concentrate in Children With Hemophilia A,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1997, 130(4):537-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/9108849 /pubmed\" id=\"9108849 \" target=\"_blank\">",
"        9108849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liesner RJ, &ldquo;Prophylaxis in Haemophilic Children,&rdquo;",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 1997, 8(Suppl 1):S7-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/9351529/pubmed\" id=\"9351529\" target=\"_blank\">",
"        9351529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharrer I, Bray GL, and Neutzling O, &ldquo;Incidence of Inhibitors in Haemophilia A Patients - A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 1999, 5(3):145-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/10444280 /pubmed\" id=\"10444280 \" target=\"_blank\">",
"        10444280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shord SS and Lindley CM, &ldquo;Coagulation Products and Their Uses,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(15):1403-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/10938981/pubmed\" id=\"10938981\" target=\"_blank\">",
"        10938981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz RS, Abildgaard CF, Aledort LM, et al, &ldquo;Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. Recombinant Factor VIII Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(26):1800-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/11/33975/abstract-text/2123300/pubmed\" id=\"2123300\" target=\"_blank\">",
"        2123300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12757 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33975=[""].join("\n");
var outline_f33_11_33975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051146\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432529\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051139\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135770\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135756\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051150\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051141\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051149\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6814324\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135804\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051153\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051138\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051137\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298758\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218001\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135766\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051145\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051148\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051136\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051152\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051143\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051154\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/1/23574?source=related_link\">",
"      Recombinant human factor VIII: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/32/22020?source=related_link\">",
"      Recombinant human factor VIII: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33976="Hepatitis E virus infection";
var content_f33_11_33976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis E virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Renuka Umashanker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33976/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/11/33976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis E virus (HEV) is an enterically-transmitted acute viral hepatitis. Infection with this virus was first documented in 1955 during an outbreak in New Delhi, India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HEV is an icosahedral, nonenveloped single stranded RNA virus that is approximately 27 to 34 nm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. It has been classified as the single member of the genus hepevirus in the family Hepeviridae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/7\">",
"     7",
"    </a>",
"    ]. Three large opening reading frames (ORFs) of the positive-sense RNA of HEV have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest ORF consists of 1693 codons; it codes for nonstructural proteins that are responsible for the processing and replication of the virus.",
"     </li>",
"     <li>",
"      The second ORF is composed of 660 codons and codes for structural proteins.",
"     </li>",
"     <li>",
"      The third ORF consists of 123 codons; although it may encode for a structural protein, its function remains undetermined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The crystal structure of HEV has revealed domains involved in cell-surface binding and cell entry, as well as potential neutralization sites (possibly a therapeutic target) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Some of the domains resemble those of other RNA viruses in the Caliciviridae and Tombusviridae families, while others are distinct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phylogenetic analysis suggests that there are four genotypes (1 through 4) and up to 24 subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/9\">",
"     9",
"    </a>",
"    ]. The association of genotypes with clinical features is incompletely understood. However, genotype 1 and 2 appear to be confined to humans while genotype 3 and 4 infect humans and animals. Genotype 3 has been associated with less virulent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of HEV, previously known as waterborne or enterically transmitted non-A, non-B hepatitis, is similar to that of hepatitis A virus (HAV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. However, HAV is more readily transmitted, causes more infections, and has a wider distribution worldwide, although HEV may be more widespread in industrialized countries than generally believed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/12-21\">",
"     12-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest incidence of HEV infection is in Asia, Africa, Middle East, and Central America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/1,22-25\">",
"     1,22-25",
"    </a>",
"    ] and HEV is the second most common cause of sporadic hepatitis in North Africa and the Middle East [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/26\">",
"     26",
"    </a>",
"    ]. In the largest reported outbreak, over 100,000 individuals were infected in the Xinjiang region of China between 1986 and 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/27\">",
"     27",
"    </a>",
"    ]. Large outbreaks have been reported in Darfur, Sudan, Chad and Uganda [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High attack rates are found in adults between 15 and 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/11,29,30\">",
"     11,29,30",
"    </a>",
"    ]. Secondary attack rates from person-to-person transmission in susceptible households are uncommon but have been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HEV is spread by fecally contaminated water in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]. Person-to-person transmission is uncommon. HEV can be transmitted by blood transfusion, particularly in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sporadic cases that have been described in western countries have mostly been limited to visitors who have traveled to areas of the world that are endemic for HEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. However, sporadic cases that were unassociated with travel have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/42\">",
"     42",
"    </a>",
"    ]. HEV can infect pigs, suggesting that some cases of human transmission may be due to contact transmission across species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Reports from Japan, Germany, and France have documented transmission from consumption of undercooked deer meat, wild boar meat, pig liver sausage, and internal organs of animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Rodents appear to serve as a reservoir in some regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/49\">",
"     49",
"    </a>",
"    ]. Zoonotic transmission is also supported by the observation of high anti-HEV seroprevalence among people with occupational contact with animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/18,50,51\">",
"     18,50,51",
"    </a>",
"    ]. Risk factors for exposure remain unclear in some patients; a sporadic case of HEV infection in the United States was reported in a patient with HIV infection without an obvious source of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, serologic evidence of hepatitis E is surprisingly common in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/50,53,54\">",
"     50,53,54",
"    </a>",
"    ]. A study based on the Third National Health and Nutrition Examination survey evaluated 18,695 serum samples for HEV antibodies collected between 1988 and 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/54\">",
"     54",
"    </a>",
"    ]. The overall seroprevalence of HEV was 21 percent. The prevalence was highest in non-Hispanic whites and those living in Midwest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metropolitan areas. The risk was also greater in those who had a pet at home or consumed liver or other organ meats more than once per month. Why clinically apparent acute HEV is not more commonly recognized given the high seroprevalence is unclear. One possibility is that exposures in the United States may be more likely to be HEV genotype 3, which may be less virulent. Other possibilities include underreporting or misclassification, or perhaps issues related to the nonspecificity of the assays used for anti-HEV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Perinatal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information regarding the vertical transmission of HEV from infected mothers to their infants. One report evaluated eight babies born to mothers infected with hepatitis E in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/55\">",
"     55",
"    </a>",
"    ]. Six infants had clinical, serologic, or virologic evidence of HEV infection. Two infants died within 24 hours of birth, one of whom had massive hepatic necrosis at autopsy. The authors concluded that HEV infection can be transmitted from mother to newborn with substantial perinatal morbidity and mortality. Similar conclusions have been reached in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HEV generally causes a self-limited acute infection, although fulminant hepatitis can develop. Chronic hepatitis does",
"    <strong>",
"     not",
"    </strong>",
"    develop after acute HEV infection, except in the transplant setting and possibly in other settings of immunosuppression (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/57\">",
"     57",
"    </a>",
"    ]. One study found that acute HEV was responsible for hepatitis in some patients who were initially believed to have drug-induced liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period of HEV infection ranges from 15 to 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2,11,59,60\">",
"     2,11,59,60",
"    </a>",
"    ]. The clinical signs and symptoms in patients with typical HEV infection are similar to those seen with other forms of acute viral hepatitis, although disease appears to be relatively severe compared with hepatitis A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/61\">",
"     61",
"    </a>",
"    ]. Prolonged cholestasis has been described in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/61\">",
"     61",
"    </a>",
"    ]. Jaundice is usually accompanied by malaise, anorexia, nausea, vomiting, abdominal pain, fever, and hepatomegaly. Other less common features include diarrhea, arthralgia, pruritus, and urticarial rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/37,62-64\">",
"     37,62-64",
"    </a>",
"    ]. Some patients have asymptomatic infection.",
"   </p>",
"   <p>",
"    Fulminant hepatitis can occur, resulting in an overall case fatality rate of 0.5 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/65\">",
"     65",
"    </a>",
"    ]. As noted above, certain genotypes have also been associated with more severe disease. However, HEV does not appear to be an important cause of fulminant hepatitis in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory findings include elevated serum concentrations of bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/37,67\">",
"     37,67",
"    </a>",
"    ]. Resolution of the abnormal biochemical tests generally occurs within one to six weeks after the onset of the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are not understood, fulminant hepatic failure occurs more frequently during pregnancy, resulting in an inordinately high mortality rate of 15 to 25 percent, primarily in women in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/3,68,69\">",
"     3,68,69",
"    </a>",
"    ]. A contributing factor may be that pregnancy predisposes to increased viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/70\">",
"     70",
"    </a>",
"    ]. Pregnant women with jaundice and acute viral hepatitis caused by HEV infection appear to have worse obstetric and fetal outcomes compared to pregnant women with jaundice and acute viral hepatitis due to other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pre-existing liver disease and those who are malnourished",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HEV can lead to hepatic decompensation in patients with pre-existing liver disease and those who are malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute and chronic infection after solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;HEV infection has been reported in recipients of solid organ transplants (kidney, liver, and kidney-pancreas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. In two reports from France, acute HEV infection was observed in 5 to 6.5 percent of solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74,79\">",
"     74,79",
"    </a>",
"    ]. An important risk factor for acute HEV infection appears to be consumption of insufficiently cooked game meat or pork products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/80\">",
"     80",
"    </a>",
"    ]. Transplant recipients are predisposed to develop severe and sometimes fatal clinical illness because of a variety of rare and less common viruses like hep E. Thus, pathogens like hep E should be considered early on as potential viral syndromes in transplant recipients.",
"   </p>",
"   <p>",
"    A subset of patients who underwent solid organ transplantation appears to develop chronic HEV infection based upon the presence of persistently elevated aminotransferase levels, detectable serum HEV RNA, histologic findings compatible with chronic viral hepatitis and absence of other viral causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74,76,77,81\">",
"     74,76,77,81",
"    </a>",
"    ]. In the non-transplant setting, HEV has not been recognized as a cause of chronic viral hepatitis except in the setting of immunosuppression. In a cohort of 700 solid organ transplant recipients, 34 (5 percent) acquired HEV infection of whom 47 percent developed chronic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/79\">",
"     79",
"    </a>",
"    ]. A similar proportion of acutely infected patients developed chronic infection (8 of 14 or 57 percent) in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74\">",
"     74",
"    </a>",
"    ]. Chronic infection appears to be related to impaired HEV-specific T-cell responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/82\">",
"     82",
"    </a>",
"    ] and has been associated with lower counts of lymphocytes and of CD2, CD3, and CD4 T cells, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74,83\">",
"     74,83",
"    </a>",
"    ] a low platelet count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/83\">",
"     83",
"    </a>",
"    ], younger age, liver transplantation, and lymphopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of chronically infected transplant recipients is incompletely understood but progressive disease has been reported. One report, for example, described a case of chronic HEV infection in a kidney transplant recipient that progressed to cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/75\">",
"     75",
"    </a>",
"    ]. Chronically infected patients also may be at risk for HEV reactivation. Such a course was described in a patient undergoing allogeneic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/84\">",
"     84",
"    </a>",
"    ]. On the other hand, it was not observed in a study of 700 patients undergoing solid organ transplantation and thus reactivation appears to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of HEV in the transplant setting is similar to the non-transplant setting and is based upon the detection of HEV in serum or stool by PCR or by the detection of anti-HEV immunoglobulin M antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Currently there are no commercial tests for HEV licensed in the United States. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no established treatment for acute or chronic HEV in transplant recipients, although a number of reports have described various approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clearance of chronic infection has been reported after reducing or withdrawing immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/83,87\">",
"       83,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case report described a patient with chronic HEV after cardiac transplantation who received a three-month course of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/88\">",
"       88",
"      </a>",
"      ]. HEV RNA became undetectable after one month of treatment and remained undetectable in stool and serum four months after treatment was completed. In another report, ribavirin monotherapy led to HEV RNA clearance in a kidney transplant patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral clearance was observed after three months of treatment with pegylated interferon in a series of three liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/90\">",
"     90",
"    </a>",
"    ]. One patient relapsed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described chronic infection with HEV in patients with non-Hodgkin lymphoma receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/91\">",
"     91",
"    </a>",
"    ], and in a patient with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/92\">",
"     92",
"    </a>",
"    ], suggesting that immunosuppression may predispose to chronic infection outside of the transplant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HEV is based upon the detection HEV in serum or stool by PCR or by the detection of IgM antibodies to HEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/93\">",
"     93",
"    </a>",
"    ]. Antibody tests against HEV alone are less than ideal since they have been associated with frequent false positive and negative results.",
"   </p>",
"   <p>",
"    There are no commercial tests for HEV licensed in the United States. However, there are research laboratories that can test for anti-HEV by Elisa or Western blot of serum and for HEV genomes by PCR of blood or feces collected during the acute phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/94\">",
"     94",
"    </a>",
"    ]. These can be located through the Centers for Disease Control and Prevention (1-800-CDC-INFO,",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     www.CDC.gov",
"    </a>",
"    ). In other countries, commercially available tests include an immunoglobulin G (IgG) assay (Abbott Laboratories, Wiesbaden, Germany or Genelabs Diagnostics, Singapore) and IgM assay (Genelabs Diagnostics, Singapore) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/95\">",
"     95",
"    </a>",
"    ]. However, as described further below, the non-PCR tests may be negative in a substantial proportion of patients with acute infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period after oral exposure is four to five weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2,59,97\">",
"     2,59,97",
"    </a>",
"    ]. HEV can be detected in stool approximately one week before the onset of illness and persists for as long as two weeks thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2,98-100\">",
"     2,98-100",
"    </a>",
"    ]. Because HEV is enterically transmitted, patients are infectious during fecal shedding. While HEV viremia and is short-lived in most patients, it can persist for up to four months (",
"    <a class=\"graphic graphic_figure graphicRef81261 \" href=\"mobipreview.htm?32/14/33006\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgM anti-HEV appears during early phase of clinical illness and disappears rapidly over four to five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/67\">",
"     67",
"    </a>",
"    ]. The IgG response appears shortly after the IgM response, and its titer increases throughout the acute phase into the convalescent phase, remaining high from 1 to as long as 14 years after the acute phase of illness in various reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/39,59,67,103,104\">",
"     39,59,67,103,104",
"    </a>",
"    ]. Simultaneous assessment of anti IgA HEV has been proposed to increase specificity, especially in patients with IgM rheumatoid factor in serum, which can cause a false-positive result on the IgM based assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of outbreaks, IgM anti-HEV has been detected by enzyme immunoassay (EIA) on more than 90 percent of patient serum samples obtained within one week to two months after the onset of illness. In one study, 100, 50, and 40 percent of sera collected from patients during hepatitis E outbreaks 1 to 40 days, three to four months, and 6 to 12 months, respectively, after the onset of jaundice tested positive for IgM anti-HEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of appearance of HEV markers is important for interpreting results of serologic markers or culture methods in the setting of acute hepatitis. Furthermore, individual measures may be negative in a substantial proportion of patients. In an illustrative series of patients with acute HEV (defined as acute hepatitis with a HEV viremia in serum and stool by cell culture and PCR), only 35, 38, and 29 percent of patients tested positive for IgM anti-HEV in serum, HEV in stool culture or HEV in serum culture, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/96\">",
"     96",
"    </a>",
"    ]. Only 3 percent were positive for IgG anti-HEV, possibly because of either failure to develop IgG anti-HEV in some patients or the delay in the appearance of anti-HEV IgG.",
"   </p>",
"   <p>",
"    In another report, the sensitivity for IgM anti-HEV was only 27 percent while specificity was 92 percent. HEV RNA was detected in 23 percent of patients followed by detection of specific IgM in 17 percent and IgG in 13 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serological and nucleic acid tests (qualitative and quantitative HEV RNA) currently represent the gold-standard for testing for HEV and have been used for both epidemiological and diagnostic purposes. Compared to single and nested gel-based reverse transcriptase polymerase chain reaction (RT-PCR), the various real-time PCR assays have a higher sensitivity, are less laborious, save time, and are less prone to cross contamination. Both assays are able to detect all four genotypes of HEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/107\">",
"     107",
"    </a>",
"    ]. Two real-time PCR assays (Taq Man chemistry and Primer-Probe Energy Transfer &ndash; PriProEt-Technique) can detect a wide range of HEV variants, all known genotypes, and are suitable for testing fecal as well as tissue samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis mainly includes other forms of viral hepatitis, drug or toxic hepatitis, ischemic hepatitis and other infectious diseases in areas where they are endemic such as leptospirosis, dengue fever, malaria, and typhoid fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphological features of HEV include those noted with cholestatic and classic types of acute viral hepatitis. Cholestatic forms are characterized by bile stasis in canaliculi and gland-like transformation of hepatocytes. In the classic presentation, the biopsy reveals focal necrosis, ballooned hepatocytes, and acidophilic degeneration of hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/1,69\">",
"     1,69",
"    </a>",
"    ]. In fatal cases submassive as well as massive hepatic necrosis is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/11,62\">",
"     11,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines against HEV are in development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/108-112\">",
"     108-112",
"    </a>",
"    ]. Two large placebo-controlled trials found that vaccination was more than 96 percent effective in preventing infection in high-risk settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little information exists regarding the efficacy of pre- or post-exposure immune globulin (IG) prophylaxis for the prevention of HEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/114\">",
"     114",
"    </a>",
"    ]. There is at present no proof that immune globulin, including lots produced in countries where HEV is endemic, confers protection against hepatitis E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers to endemic areas should engage in practices that may prevent infection, such as avoiding drinking water of unknown purity, uncooked shellfish, and uncooked fruits or vegetables.",
"   </p>",
"   <p>",
"    Treatment of infection remains supportive. Case reports have suggested a benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , suggesting it might be an option for chronic HEV infection, but more data are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33976/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis E virus (HEV) is a single stranded RNA virus that causes a self-limited, enterically-transmitted acute viral hepatitis. Phylogenetic analysis suggests that there are 4 genotypes (1 through 4) and up to 24 subtypes. The association of genotypes with clinical features is incompletely understood, although genotype 3 has been associated with milder disease.",
"     </li>",
"     <li>",
"      Hepatitis is usually spread by the fecal-oral route and large scale outbreaks have been associated with contaminated water sources.",
"     </li>",
"     <li>",
"      The clinical features of acute HEV infection are similar to those seen with other forms of acute viral hepatitis, although disease appears to be relatively severe compared with hepatitis A. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of acute HEV resolve. Chronic HEV has been described in the setting of organ transplantation and potent immunosuppression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute and chronic infection after solid organ transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fulminant hepatitis is more likely in those who are pregnant and in those who are malnourished or have pre-existing liver disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HEV is based upon the detection of the HEV genome in serum or feces by PCR or by the detection of IgM antibodies to HEV. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is supportive. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An effective vaccine against HEV has been developed but is not yet commercially available. Travelers to endemic areas (ie, Asia, Africa, Middle East, and Central America) should engage in practices that may prevent infection, such as avoiding drinking water of unknown purity, uncooked shellfish, and uncooked fruits or vegetables.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/1\">",
"      GUPTA DN, SMETANA HF. The histopathology of viral hepatitis as seen in the Delhi epidemic (1955-56). Indian J Med Res 1957; 45:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/2\">",
"      Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 1983; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/3\">",
"      Kane MA, Bradley DW, Shrestha SM, et al. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984; 252:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/4\">",
"      Krawczynski K, Bradley DW. Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. J Infect Dis 1989; 159:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/5\">",
"      Yamashita T, Mori Y, Miyazaki N, et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A 2009; 106:12986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/6\">",
"      Guu TS, Liu Z, Ye Q, et al. Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci U S A 2009; 106:12992.",
"     </a>",
"    </li>",
"    <li>",
"     Emerson SU. Hepevirus. In: Virus Taxonomy, VIIth report of the ICTV, Fauquet CM, et al (Eds), Elsevier Academic Press, San Diego 2005. p.853.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/8\">",
"      Koonin EV, Gorbalenya AE, Purdy MA, et al. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci U S A 1992; 89:8259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/9\">",
"      Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 2006; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/10\">",
"      Inoue J, Nishizawa T, Takahashi M, et al. Analysis of the full-length genome of genotype 4 hepatitis E virus isolates from patients with fulminant or acute self-limited hepatitis E. J Med Virol 2006; 78:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/11\">",
"      Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980; 68:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/12\">",
"      Tang YW, Wang JX, Xu ZY, et al. A serologically confirmed, case-control study, of a large outbreak of hepatitis A in China, associated with consumption of clams. Epidemiol Infect 1991; 107:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/13\">",
"      Quintana A, Sanchez L, Larralde O, Anderson D. Prevalence of antibodies to hepatitis E virus in residents of a district in Havana, Cuba. J Med Virol 2005; 76:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/14\">",
"      Lynch M, O'Flynn N, Cryan B, et al. Hepatitis E in Ireland. Eur J Clin Microbiol Infect Dis 1995; 14:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/15\">",
"      Sylvan SP. The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection. Scand J Infect Dis 1998; 30:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/16\">",
"      Christensen PB, Engle RE, Jacobsen SE, et al. High prevalence of hepatitis E antibodies among Danish prisoners and drug users. J Med Virol 2002; 66:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/17\">",
"      Ibarra HV, Riedemann SG, Siegel FG, et al. Hepatitis E virus in Chile. Lancet 1994; 344:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/18\">",
"      Banks M, Bendall R, Grierson S, et al. Human and porcine hepatitis E virus strains, United Kingdom. Emerg Infect Dis 2004; 10:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/19\">",
"      Stefanidis I, Zervou EK, Rizos C, et al. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. Int J Artif Organs 2004; 27:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/20\">",
"      Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat 1996; 3:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/21\">",
"      Clemente-Casares P, Pina S, Buti M, et al. Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis 2003; 9:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/22\">",
"      Arankalle VA, Chadha MS, Mehendale SM, Banerjee K. Outbreak of enterically transmitted non-A, non-B hepatitis among schoolchildren. Lancet 1988; 2:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/23\">",
"      Belabbes EH, Bouguermouh A, Benatallah A, Illoul G. Epidemic non-A, non-B viral hepatitis in Algeria: strong evidence for its spreading by water. J Med Virol 1985; 16:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/24\">",
"      Tsega E, Krawczynski K, Hansson BG, et al. Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. J Med Virol 1991; 34:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/25\">",
"      Vel&aacute;zquez O, Stetler HC, Avila C, et al. Epidemic transmission of enterically transmitted non-A, non-B hepatitis in Mexico, 1986-1987. JAMA 1990; 263:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/26\">",
"      Emerson SU, Purcell RH. Running like water--the omnipresence of hepatitis E. N Engl J Med 2004; 351:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/27\">",
"      Zhuang H. Hepatitis E and strategies for its control. Viral Hepatitis in China: Problems and Control Strategies. Monogr Virol 1992; 19:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/28\">",
"      Nicand E, Armstrong GL, Enouf V, et al. Genetic heterogeneity of hepatitis E virus in Darfur, Sudan, and neighboring Chad. J Med Virol 2005; 77:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/29\">",
"      Arankalle VA, Tsarev SA, Chadha MS, et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995; 171:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/30\">",
"      Gust ID, Purcell RH. Report of a workshop: waterborne non-A, non-B hepatitis. J Infect Dis 1987; 156:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/31\">",
"      Villarejos VM, Serra J, Anderson-Visona K, Mosley JW. Hepatitis A virus infection in households. Am J Epidemiol 1982; 115:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/32\">",
"      Teshale EH, Grytdal SP, Howard C, et al. Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clin Infect Dis 2010; 50:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/33\">",
"      Naik SR, Aggarwal R, Salunke PN, Mehrotra NN. A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull World Health Organ 1992; 70:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/34\">",
"      Arankalle VA, Chobe LP. Retrospective analysis of blood transfusion recipients: evidence for post-transfusion hepatitis E. Vox Sang 2000; 79:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/35\">",
"      Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 2004; 44:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/36\">",
"      Khuroo MS, Kamili S, Yattoo GN. Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 2004; 19:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Hepatitis E among U.S. travelers, 1989-1992. MMWR Morb Mortal Wkly Rep 1993; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/38\">",
"      De Cock KM, Bradley DW, Sandford NL, et al. Epidemic non-A, non-B hepatitis in patients from Pakistan. Ann Intern Med 1987; 106:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/39\">",
"      Dawson GJ, Mushahwar IK, Chau KH, Gitnick GL. Detection of long-lasting antibody to hepatitis E virus in a US traveller to Pakistan. Lancet 1992; 340:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/40\">",
"      Fortier D, Treadwell TL, Koff RS. Enterically transmitted non-A, non-B hepatitis: importation from Mexico to Massachusetts. N Engl J Med 1989; 320:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/41\">",
"      Roman&ograve; L, Paladini S, Tagliacarne C, et al. Hepatitis E in Italy: a long-term prospective study. J Hepatol 2011; 54:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/42\">",
"      Ijaz S, Arnold E, Banks M, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 2005; 192:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/43\">",
"      Arankalle VA, Chobe LP, Joshi MV, et al. Human and swine hepatitis E viruses from Western India belong to different genotypes. J Hepatol 2002; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/44\">",
"      Rutjes SA, Lodder WJ, Lodder-Verschoor F, et al. Sources of hepatitis E virus genotype 3 in The Netherlands. Emerg Infect Dis 2009; 15:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/45\">",
"      Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/46\">",
"      Li TC, Chijiwa K, Sera N, et al. Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis 2005; 11:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/47\">",
"      Wichmann O, Schimanski S, Koch J, et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 2008; 198:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/48\">",
"      Colson P, Borentain P, Queyriaux B, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010; 202:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/49\">",
"      He J, Innis BL, Shrestha MP, et al. Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal. J Clin Microbiol 2006; 44:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/50\">",
"      Meng XJ, Wiseman B, Elvinger F, et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 2002; 40:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/51\">",
"      Karetnyi YV, Gilchrist MJ, Naides SJ. Hepatitis E virus infection prevalence among selected populations in Iowa. J Clin Virol 1999; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/52\">",
"      Curry JA, Adams N, Crum-Cianflone NF. Acute hepatitis E virus infection in an HIV-infected person in the United States. Ann Intern Med 2009; 150:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/53\">",
"      Thomas DL, Yarbough PO, Vlahov D, et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol 1997; 35:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/54\">",
"      Kuniholm MH, Purcell RH, McQuillan GM, et al. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009; 200:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/55\">",
"      Khuroo MS, Kamili S, Jameel S. Vertical transmission of hepatitis E virus. Lancet 1995; 345:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/56\">",
"      Kumar RM, Uduman S, Rana S, et al. Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol 2001; 100:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/57\">",
"      Khuroo MS, Saleem M, Teli MR, Sofi MA. Failure to detect chronic liver disease after epidemic non-A, non-B hepatitis. Lancet 1980; 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/58\">",
"      Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/59\">",
"      Chauhan A, Jameel S, Dilawari JB, et al. Hepatitis E virus transmission to a volunteer. Lancet 1993; 341:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/60\">",
"      Bryan JP, Tsarev SA, Iqbal M, et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J Infect Dis 1994; 170:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/61\">",
"      Chau TN, Lai ST, Tse C, et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. Am J Gastroenterol 2006; 101:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/62\">",
"      Morrow RH Jr, Smetana HF, Sai FT, Edgcomb JH. Unusual features of viral hepatitis in Accra, Ghana. Ann Intern Med 1968; 68:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/63\">",
"      Herrera JL. Hepatitis E as a cause of acute non-A, non-B hepatitis. Arch Intern Med 1993; 153:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/64\">",
"      Jameel S, Durgapal H, Habibullah CM, et al. Enteric non-A, non-B hepatitis: epidemics, animal transmission, and hepatitis E virus detection by the polymerase chain reaction. J Med Virol 1992; 37:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/65\">",
"      Centers for Disease Control (CDC). Enterically transmitted non-A, non-B hepatitis--East Africa. MMWR Morb Mortal Wkly Rep 1987; 36:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/66\">",
"      Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci 2006; 51:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/67\">",
"      Favorov MO, Fields HA, Purdy MA, et al. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol 1992; 36:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/68\">",
"      Khuroo MS, Teli MR, Skidmore S, et al. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981; 70:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/69\">",
"      Asher LV, Innis BL, Shrestha MP, et al. Virus-like particles in the liver of a patient with fulminant hepatitis and antibody to hepatitis E virus. J Med Virol 1990; 31:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/70\">",
"      Kar P, Jilani N, Husain SA, et al. Does hepatitis E viral load and genotypes influence the final outcome of acute liver failure during pregnancy? Am J Gastroenterol 2008; 103:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/71\">",
"      Patra S, Kumar A, Trivedi SS, et al. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med 2007; 147:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/72\">",
"      Hamid SS, Atiq M, Shehzad F, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002; 36:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/73\">",
"      Kumar Acharya S, Kumar Sharma P, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/74\">",
"      Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/75\">",
"      G&eacute;rolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008; 358:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/76\">",
"      Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008; 14:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/77\">",
"      Kamar N, Mansuy JM, Cointault O, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008; 8:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/78\">",
"      Khuroo MS, Khuroo MS. Hepatitis E virus. Curr Opin Infect Dis 2008; 21:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/79\">",
"      Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis 2011; 17:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/80\">",
"      Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis 2010; 202:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/81\">",
"      Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/82\">",
"      Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012; 55:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/83\">",
"      Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/84\">",
"      le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 2009; 58:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/85\">",
"      Baylis SA, Hanschmann KM, Bl&uuml;mel J, et al. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol 2011; 49:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/86\">",
"      Khudyakov Y, Kamili S. Serological diagnostics of hepatitis E virus infection. Virus Res 2011; 161:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/87\">",
"      Aggarwal R, Jameel S. Hepatitis E. Hepatology 2011; 54:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/88\">",
"      Chaillon A, Sirinelli A, De Muret A, et al. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. J Heart Lung Transplant 2011; 30:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/89\">",
"      Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology 2010; 139:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/90\">",
"      Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010; 50:e30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/91\">",
"      Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009; 150:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/92\">",
"      Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/93\">",
"      Takahashi M, Kusakai S, Mizuo H, et al. Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. J Clin Microbiol 2005; 43:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/94\">",
"      Emerson SU, Purcell RH. Hepatitis E. Pediatr Infect Dis J 2007; 26:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/95\">",
"      Elkady A, Tanaka Y, Kurbanov F, et al. Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection. J Gastroenterol 2007; 42:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/96\">",
"      Zaki Mel-S, Foud MF, Mohamed AF. Value of hepatitis E virus detection by cell culture compared with nested PCR and serological studies by IgM and IgG. FEMS Immunol Med Microbiol 2009; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/97\">",
"      Krawczynski K, Aggarwal R, Kamili S. Hepatitis E. Infect Dis Clin North Am 2000; 14:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/98\">",
"      Khuroo MS. Hepatitis E: the enterically transmitted non-A, non-B hepatitis. Indian J Gastroenterol 1991; 10:96.",
"     </a>",
"    </li>",
"    <li>",
"     Krawczynski K, McCaustland K, Mast E, et al. Elements of pathogenesis of HEV infection in man and experimentally infected primates. In: Enterically-transmitted Hepatitis Viruses, Buisson Y, Coursage P, Kane M (Eds), La Simarre, Tours, 1996. p.317.",
"    </li>",
"    <li>",
"     Zhuang H, CAB X-Y, Liu CB, et al. Enterically transmitted non-A, non-B hepatitis in China. In: Viral Hep C, D and E, Shikata T, Purcell RH, Uchida T (Eds), Excerpta Medica, Amsterdam 1991. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/101\">",
"      Koshy A, Grover S, Hyams KC, et al. Short-term IgM and IgG antibody responses to hepatitis E virus infection. Scand J Infect Dis 1996; 28:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/102\">",
"      Clayson ET, Myint KS, Snitbhan R, et al. Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 1995; 172:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/103\">",
"      Dawson GJ, Chau KH, Cabal CM, et al. Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides. J Virol Methods 1992; 38:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/104\">",
"      Khuroo MS, Kamili S, Dar MY, et al. Hepatitis E and long-term antibody status. Lancet 1993; 341:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/105\">",
"      Favorov MO, Khudyakov YE, Mast EE, et al. IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. J Med Virol 1996; 50:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/106\">",
"      El-Sayed Zaki M, El-Deen Zaghloul MH, El Sayed O. Acute sporadic hepatitis E in children: diagnostic relevance of specific immunoglobulin M and immunoglobulin G compared with nested reverse transcriptase PCR. FEMS Immunol Med Microbiol 2006; 48:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/107\">",
"      Gyarmati P, Mohammed N, Norder H, et al. Universal detection of hepatitis E virus by two real-time PCR assays: TaqMan and Primer-Probe Energy Transfer. J Virol Methods 2007; 146:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/108\">",
"      Hong Y, Ruan B, Yang LH, et al. Hepatitis E virus chimeric DNA vaccine elicits immunologic response in mice. World J Gastroenterol 2005; 11:6713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/109\">",
"      Zhou YX, Lee MY, Ng JM, et al. A truncated hepatitis E virus ORF2 protein expressed in tobacco plastids is immunogenic in mice. World J Gastroenterol 2006; 12:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/110\">",
"      Purcell RH, Nguyen H, Shapiro M, et al. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 2003; 21:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/111\">",
"      Zhang M, Emerson SU, Nguyen H, et al. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. Vaccine 2002; 20:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/112\">",
"      Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/113\">",
"      Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/114\">",
"      Tsarev SA, Tsareva TS, Emerson SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A 1994; 91:10198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/115\">",
"      Khuroo MS, Dar MY. Hepatitis E: evidence for person-to-person transmission and inability of low dose immune serum globulin from an Indian source to prevent it. Indian J Gastroenterol 1992; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33976/abstract/116\">",
"      Mallet V, Nicand E, Sultanik P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010; 153:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3677 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33976=[""].join("\n");
var outline_f33_11_33976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Perinatal transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pre-existing liver disease and those who are malnourished",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute and chronic infection after solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3677|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/14/33006\" title=\"figure 1\">",
"      HEV serologic course",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33977="Treatment of advanced, unresectable gallbladder cancer";
var content_f33_11_33977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of advanced, unresectable gallbladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Bhoomi Mehrotra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33977/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/11/33977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy; fewer than 5000 new cases are diagnosed each year in the United States. The majority are found incidentally in patients undergoing exploration for cholelithiasis; a tumor will be found in 1 to 2 percent of such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The poor prognosis is thought to be related to advanced stage at diagnosis, which is due both to the anatomic position of the gallbladder, and the vagueness and nonspecificity of symptoms.",
"   </p>",
"   <p>",
"    Surgery is the only potentially curative modality for patients with GBC. However, only a minority of patients are eligible for curative intent surgery because of disease extent (either locoregionally advanced and unresectable because of local invasion into critical structures or metastasized beyond locoregional confines). For the remainder, treatment is palliative in nature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of palliation for advanced GBC (as for other pancreaticobiliary cancers) is relief of pain and jaundice along with prolongation of life. Patients who have pain from local growth may benefit from radiation therapy with or without concomitant chemotherapy. Although biliary or intestinal bypass can be considered, percutaneous or endoscopic approaches are generally preferred, given the limited median survival in patients with advanced disease (generally, less than six months).",
"   </p>",
"   <p>",
"    Here we will discuss the treatment of advanced unresectable gallbladder cancer. The epidemiology, risk factors, clinical features, and diagnostic evaluation of GBC, and treatment for localized, potentially resectable disease are covered separately, as is treatment for advanced bile duct cancer (cholangiocarcinoma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PALLIATION OF OBSTRUCTIVE JAUNDICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice caused by biliary obstruction is the presenting feature in 30 to 60 percent of patients with GBC; the usual cause is direct infiltration of the common hepatic duct by tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who present with jaundice are usually not amenable to a curative resection.",
"   </p>",
"   <p>",
"    Although biliary or intestinal bypass can be considered for palliation of obstructive jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/6\">",
"     6",
"    </a>",
"    ], stenting via a percutaneous or endoscopic approach is generally preferred, given the limited median survival in patients with advanced disease (generally, less than six months). Drainage of as little as 30 percent of the liver parenchyma (as can be accomplished by unilateral drainage of one lobe of the liver) may be sufficient to adequately palliate jaundice and relieve pruritus.",
"   </p>",
"   <p>",
"    Most stents are placed endoscopically. Although endoscopic methods appear to be better than percutaneous drainage in patients with lower bile duct obstruction caused by pancreatic and periampullary cancers, success rates may be lower and complication rates (particularly cholangitis) higher with the endoscopic approach in patients with malignant hilar obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous and endoscopic approaches to biliary drainage were directly compared in a trial in which 54 consecutive patients with GBC and a Bismuth type II or III biliary obstruction (",
"    <a class=\"graphic graphic_figure graphicRef75886 \" href=\"mobipreview.htm?0/36/582\">",
"     figure 1",
"    </a>",
"    ) who were not suitable for resection were randomly assigned to percutaneous transhepatic biliary drainage or endoscopic stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/7\">",
"     7",
"    </a>",
"    ]. Successful drainage was more often achieved with percutaneous drainage (89 versus 41 percent), while early cholangitis was a more common complication of endoscopic stenting (48 versus 11 percent). Rates of stent occlusion (32 versus 39 percent) and median survival (60 days in both groups) were not significantly different.",
"   </p>",
"   <p>",
"    However, the success rate with endoscopic drainage in this study (41 percent) is much lower than that usually seen in clinical practice, and it is not surprising that this group had a higher complication rate due to the high rate of unsuccessful instrumentation of an obstructed biliary system. Other complications may be more frequent with the percutaneous approach (eg, bile leaks and bleeding), potentially increasing morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Furthermore, percutaneous stents are usually left to open drainage external to the body, at least initially, and this is often inconvenient to the patient. As a result, in most institutions, an initial endoscopic attempt at drainage is usually preferred, as long as local endoscopic expertise is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RT WITH OR WITHOUT CHEMOTHERAPY FOR LOCALLY ADVANCED NONMETASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the rarity of GBC, management protocols for nonresectable disease are commonly extrapolated from studies of tumors of the pancreas or bile ducts (cholangiocarcinoma). Like these two entities, dissemination of GBC is thought to be mainly locoregional, although GBC has a higher propensity for distant involvement than does cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/10\">",
"     10",
"    </a>",
"    ]. In spite of this, the two tumors are generally managed similarly when they are locoregionally advanced and unresectable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with cholangiocarcinoma, external beam radiation therapy (EBRT) may be considered for palliative management of patients with locally advanced unresectable disease, particularly if patients are symptomatic. At the time of exploration, the margins of unresectable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    residual disease are often marked with radiopaque clips to facilitate treatment planning.",
"   </p>",
"   <p>",
"    There are very few data on the outcome of primary RT for unresectable GBC. Published retrospective series are small, contain small numbers of GBCs relative to extrahepatic cholangiocarcinomas, and are heterogeneous with regard to treatment technique and RT dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The available data suggest that tumor control is rarely achieved with RT alone, in part because of the proximity of dose-limiting normal tissue that limits the potential to deliver an effective tumoricidal dose.",
"   </p>",
"   <p>",
"    Most patients with locally advanced unresectable disease receive a combination of chemotherapy and RT to take advantage of the radiation-sensitizing properties of certain chemotherapeutic agents, although there are few data validating this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. With or without chemotherapy, the first site of failure in patients with a margin-positive resection is usually locoregional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, whether the use of chemoradiotherapy (or even RT alone) favorably impacts survival in the setting of locally advanced nonmetastatic disease is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/11,16-19\">",
"     11,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite uncertainty as to benefit, chemoradiotherapy is an appropriate choice for locoregional therapy of a locally advanced unresectable GBC. As with locally advanced unresectable cholangiocarcinoma, most institutions utilize infusional 5-FU during a course of external beam RT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the National Comprehensive Cancer Network and the European Society for Medical Oncology suggest concomitant fluoropyrimidine-based chemoradiotherapy as a therapeutic option to palliative chemotherapy for patients with locally advanced, unresectable GBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy has had limited success in the treatment of advanced GBC. Most published series are small and consist of a mixture of GBC and cholangiocarcinoma; some include pancreatic and hepatic cancers as well. However, tumors of the gallbladder, biliary tract, pancreas and liver behave differently with respect to treatment response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported objective response rates with chemotherapy in patients with GBC are as high as 50 to 60 percent. There are only limited data evaluating the impact of treatment on survival. In the only randomized trial comparing systemic chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [GEMOX] or 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) versus best supportive care alone in 81 patients with unresectable GBC, median overall survival was 4.5, 4.6, and 9.5 months in the basic supportive care,",
"    <span class=\"nowrap\">",
"     FU/leucovorin",
"    </span>",
"    and GEMOX groups, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the studies described below have been conducted in patients with adenocarcinoma, the most common histology of GBC. There are no available data that are specific to the treatment of advanced adenosquamous or squamous cell gallbladder cancers, and these patients are managed similarly. Treatment of patients with advanced small cell carcinoma of the gallbladder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link&amp;anchor=H14#H14\">",
"     \"Extrapulmonary small cell cancer\", section on 'Gallbladder ESCC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     5-FU-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In past studies, objective response rates for 5-FU alone or 5-FU-based combination therapies ranged from 0 to 34 percent, and median survival was typically less than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Many but not all more recent series using either infusional 5-FU in combination regimens or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU report higher response rates and marginally longer survival (but still less than one year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/32-39\">",
"     32-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Infusional 5-FU plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusional 5-FU has been combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in at least two trials. In one, 5-FU (1",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion daily for five days) plus cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 2) resulted in partial remission in six patients (24 percent); one was a long-term survivor after receiving additional local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/32\">",
"     32",
"    </a>",
"    ]. Median survival for patients with GBC was 11.5 months.",
"   </p>",
"   <p>",
"    In the second report, 5-FU (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous intravenous infusion throughout the treatment) was given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, every 21 days), the ECF regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/38\">",
"     38",
"    </a>",
"    ]. The objective response rate was 40 percent, and the median duration of response was 10 months. A somewhat lower response rate was noted in a subsequent phase III trial which showed similar therapeutic efficacy of the ECF regimen as compared to 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (objective response rate 19 versus 15 percent, median overall survival 9 versus 12 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/40\">",
"     40",
"    </a>",
"    ]. ECF was associated with significantly less acute toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Leucovorin-modulated 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    -modulated 5-FU has a favorable toxicity profile but only modest antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/26,35,39\">",
"     26,35,39",
"    </a>",
"    ] , and no impact on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Capecitabine with and without oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    , an orally active fluoropyrimidine derivative, appears to be an active agent for GBC, both as a single agent and in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/23,41,42\">",
"     23,41,42",
"    </a>",
"    ]. In a report of 63 patients with hepatobiliary malignancies, which included eight with GBC, capecitabine (2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for 14 of every 21 days) produced an objective response in four (50 percent) of the patients with GBC, two of which were complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, there were no responses among those with cholangiocarcinoma.",
"   </p>",
"   <p>",
"    In another trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 to 14) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over one hour on day 1) was administered to 65 evaluable patients with biliary tract tumors, 27 with GBC, the remainder cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/41\">",
"     41",
"    </a>",
"    ]. Of the 27 patients with GBC, there was one complete and seven partial responses; an additional nine had stable disease (total disease control rate 63 percent). The median survival was 11.3 months. Treatment was well tolerated with only mild hematologic toxicity, grade 3 or 4 peripheral neuropathy in 11 patients in the entire cohort, and two hypersensitivity reactions to oxaliplatin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gemcitabine and gemcitabine-based combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is an active agent, both as monotherapy and in combination regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/24,36,43-57\">",
"     24,36,43-57",
"    </a>",
"    ]. Reported clinical benefit rates (partial response plus stable disease) with single agent gemcitabine (1000 to 1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every four weeks) are in the range of 15 to 60 percent, although objective response rates are as low as 7 percent. In most studies, median survival is 11 months or less, although three phase II trials report median survival durations of 13 to 16 months with the combination of gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/45,55,56\">",
"     45,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gemcitabine plus 5-FU and leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    adds benefit to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone remains an open question. In a phase II multicenter trial involving 40 patients with biliary cancers (22 with GBC), gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every five weeks) was given alone (n = 18) or gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8, every 21 days) was given with 5-FU (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    bolus followed by 22-hour infusion of 600",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    every 21 days) and leucovorin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours day 1, every 21 days, n = 22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/58\">",
"     58",
"    </a>",
"    ]. Partial responses were noted in 22 and 36 percent of patients receiving gemcitabine alone or with 5-FU and leucovorin, respectively, and the median time to progression was 3.4 and 4.1 months, respectively. Toxicity was mild and manageable, particularly with gemcitabine alone.",
"   </p>",
"   <p>",
"    A second multicenter phase II trial of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"      gemcitabine",
"     </a>",
"     /5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    reported three partial responses among 14 cases of gallbladder cancer (objective response rate 21 percent), and the median time to progression and overall survival were 5.2 and 7.2 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gemcitabine plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and the oral 5-FU prodrug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    seems to be associated with higher response rates than gemcitabine plus 5-FU for advanced biliary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/44-46,55,56\">",
"     44-46,55,56",
"    </a>",
"    ], and at least three phase II trials report a median survival of 13 to 16 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/45,55,56\">",
"     45,55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 75 patients (27 GBC, 3 ampulla of Vater, and the remainder cholangiocarcinoma),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (650",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      twice daily for 14 of every 21 day cycle) was well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/55\">",
"       55",
"      </a>",
"      ]. There were 22 objective responses (three complete), which were seen in both tumor types. The median progression-free and overall survival rates were 6.2 and 12.7 months, respectively.",
"     </li>",
"     <li>",
"      A smaller phase II trial of the same combination in 22 and 12 patients with GBC, respectively, reported objective responses in 6 of 22 (28 percent) and 2 of 12 (17 percent); the median survival duration was 14 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/44,56\">",
"       44,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of 24 patients with GBC, treated with the same doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      but a higher",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      dose (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days), one-third had a partial response, and the median survival was 16 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all studies suggest prolongation of survival with this combination however [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Southwest Oncology Group (SWOG) studied",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 100 minutes on days 1 and 8) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (650",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days) in 57 patients with unresectable or metastatic gallbladder cancer (n = 17) or cholangiocarcinoma (n = 35) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/46\">",
"       46",
"      </a>",
"      ]. In a preliminary report, there were nine partial responses (response rate 18 percent), and 14 (27 percent) had stable disease as the best response. Treatment was reasonably well tolerated with only four patients developing grade 4 neutropenia. Median survival was 7 months.",
"     </li>",
"     <li>",
"      In a second study of combined therapy in 45 patients, 22 with GBC, the remainder cholangiocarcinoma, the median survival duration for the entire group was 14 months, but according to tumor type, it was 19 months for cholangiocarcinoma and only 6.6 months for GBC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gemcitabine plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is also an active regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/39,47,48,59,60\">",
"     39,47,48,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    over gemcitabine alone was shown in the multicenter ABC-02 trial, in which 410 patients with locally advanced (25 percent) or metastatic bile duct (n = 242), gallbladder (n = 148) or ampullary (n = 20) cancer were randomly assigned to six courses of cisplatin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on days 1 and 8, every 21 days, or gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, 15, every 28 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of 8.2 months, median overall survival was significantly greater with combination therapy (11.7 versus 8.1 months), as was median PFS (8 versus 5 months). Toxicity was roughly comparable in both groups with the exception of significantly higher rates of grade 3 or 4 neutropenia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (25 versus 17 percent), and of grade 3 or 4 abnormal liver function with gemcitabine alone (27 versus 17 percent).",
"   </p>",
"   <p>",
"    The authors concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    should be considered the reference regimen for advanced biliary cancer. However,",
"    <span class=\"nowrap\">",
"     gemcitabine/cisplatin",
"    </span>",
"    combination has not been directly compared to other gemcitabine combinations (eg, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) or capecitabine plus oxaliplatin in randomized trials.",
"   </p>",
"   <p>",
"    A pooled analysis of 104 trials of a variety of chemotherapy regimens in advanced biliary cancer (all but three uncontrolled, only one a phase III randomized trial, but not including the ABC trial described above) concluded that the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"      gemcitabine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"    </span>",
"    combination offered the highest rates of objective response and of tumor control (objective response plus stable disease) compared to either gemcitabine-free or cisplatin-free regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/61\">",
"     61",
"    </a>",
"    ]. However, this did not translate into significant benefit in terms of either time to tumor progression or median overall survival. Thus, in our view,",
"    <span class=\"nowrap\">",
"     gemcitabine/cisplatin",
"    </span>",
"    should be considered a standard option for advanced gallbladder cancer, but not the definitive reference standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gemcitabine plus carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    reduces the severity of nonhematologic toxicity, but myelosuppression is sometimes worse. In a trial involving 20 patients with advanced GBC, the response rate with 21-day cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8) plus carboplatin (administered at an area under the curve of concentration x time [AUC] of 5 on day 1, according to the Calvert formula (Carboplatin dose [mg] = Target AUC X [estimated creatinine clearance + 25]).) was 37 percent, and there were four complete responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/49\">",
"     49",
"    </a>",
"    ]. The median overall survival was approximately 11 months. Treatment was well tolerated, with grade 3 or 4 neutropenia in only 20 percent, vomiting or diarrhea in 12 and 9 percent, respectively, stomatitis in 5 percent, and thrombocytopenia in 5 percent.",
"    <br/>",
"    <br/>",
"    However, there is marked interindividual variability in hematologic tolerance of this combination. A pharmacokinetic analysis suggested that in combination with gemcitabine, dosing of carboplatin at an AUC 5 was associated with grade 3 or 4 thrombocytopenia rates of 38 and 31 percent for pretreated and non-pretreated patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues specific to dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gemcitabine plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some have reported antitumor efficacy and good tolerability for GEMOX (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/50,51,63\">",
"     50,51,63",
"    </a>",
"    ]. In a representative phase II study, the response rate was 36 percent, and median overall survival duration was 14.3 months using every other week gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) and oxaliplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 2) in a select group of 31 previously untreated patients with advanced biliary cancer (19 with GBC), a good performance status, and a serum bilirubin level &lt;2.5 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/50\">",
"     50",
"    </a>",
"    ]. Results were less favorable in the 25 other patients with poorer performance status, receiving second or third line therapy, or with a higher bilirubin level (response rate 22 percent, median survival 7.6 months).",
"   </p>",
"   <p>",
"    Others report a far lower objective response rate with this regimen in advanced gallbladder cancer (1 of 23 patients, 4 percent) as compared to non-gallbladder biliary tract carcinomas (9 of 44, 21 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of GEMOX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H5864415\">",
"     'GEMOX plus bevacizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Gemcitabine plus oxaliplatin and 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from a multicenter phase II trial of 37 patients with chemotherapy-naive advanced or metastatic gall bladder carcinoma using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and a weekly infusion of 5-FU seem promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/52\">",
"     52",
"    </a>",
"    ]. The regimen consisted of gemcitabine (900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a 30 minute infusion) followed 30 minutes later by oxaliplatin (65",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours) and 5-FU (1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a 24 hour infusion), with all drugs administered on days 1 and 8 every three weeks. Eight patients (23 percent) had a partial response, rates of grade 3 or 4 hematologic and nonhematologic toxicity were low, and the median survival was 10 months, with 34 percent of patients still alive at one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) was shown in a trial of 25 patients with unresectable or metastatic biliary tract carcinoma, in which there were two complete and three partial responses (overall response rate 20 percent); grade 3 or 4 neutropenia complicated therapy in 56 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/65\">",
"     65",
"    </a>",
"    ]. Unfortunately, preliminary results suggest minimal activity for the combination of docetaxel and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169426\">",
"    <span class=\"h3\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early data suggest possible benefit from blockade of the epidermal growth factor receptor (EGFR) by the oral tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/67\">",
"     67",
"    </a>",
"    ]. In one study, 42 patients with advanced biliary cancer (not stratified according to primary site), 57 percent of whom had received prior chemotherapy, received erlotinib (150 mg daily). There were three partial responses (two with documented expression of EGFR) and seven additional patients remained progression-free at six months. All responding patients had mild (grade 1 or 2) skin toxicity.",
"   </p>",
"   <p>",
"    Further experience with this drug is needed, particularly combined with cytotoxic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169387\">",
"    <span class=\"h3\">",
"     Erlotinib plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) is overexpressed in biliary tract cancers and has been proposed as a therapeutic target [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/68\">",
"     68",
"    </a>",
"    ]. The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting VEGF, in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    was addressed in a multinational phase II study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/69\">",
"     69",
"    </a>",
"    ]. Fifty-three patients with advanced cholangiocarcinoma (n = 43) or gallbladder cancer (n = 10) received bevacizumab (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) plus erlotinib (150 mg once daily). Nine patients achieved a PR, which was sustained beyond four weeks in six (12 percent), with a median response duration of 8.4 months. Stable disease was documented in 51 percent. In the entire group, the median time to disease progression was 4.4 months, and median overall survival 9.9 months. Results were not stratified according to tumor location. Four patients (8 percent) developed grade 4 toxicity (cerebral ischemia or thrombosis), and the most frequent grade 3 toxicity was skin rash (3 patients), although in all, 40 patients developed a rash of any grade during therapy.",
"   </p>",
"   <p>",
"    Whether results from this biologic-only combination are better than can be achieved with conventional cytotoxic therapy will require a randomized trial. This regimen is associated with significant cost (nearly $10,000 per month).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5864415\">",
"    <span class=\"h3\">",
"     GEMOX plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy for the combination of GEMOX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was suggested in a phase II trial in which 35 patients (all but three previously untreated) with advanced biliary tract cancer (25 cholangiocarcinoma, 10 gallbladder cancer) received bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on days 1 and 15) followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per minute) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    with cycles repeated every 28 days. Fourteen patients had a confirmed partial response (41 percent); among the 10 patients with GBC who were eligible for analysis, the median PFS and overall survival durations were 6.1 and 8.5 months, respectively. Bevacizumab-related toxicities included grade 3 or 4 hypertension in 5, proteinuria in one, thrombosis in two, and cardiac ischemia in one. &nbsp;",
"   </p>",
"   <p>",
"    Whether these results are better than can be achieved with GEMOX alone will require a randomized trial. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Gemcitabine plus oxaliplatin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169440\">",
"    <span class=\"h3\">",
"     Lapatanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    , an orally-active dual inhibitor of EGFR and HER2 (EGFR-2), was evaluated in a study of 17 evaluable patients with advanced bile duct or gall bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/70\">",
"     70",
"    </a>",
"    ]. No responses were observed, but five patients had stable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SECOND-LINE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"standard\" second-line therapy after failure of first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    . For patients who retain a good performance status, an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen could be tried (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus oxaliplatin [CAPOX or XELOX] or short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and oxaliplatin (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 1",
"    </a>",
"    )). In a preliminary report of 18 patients with advanced gemcitabine-refractory pancreaticobiliary cancer who received CAPOX, one had a partial response, eight others had stable disease, and the median progression-free survival was approximately 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/31/4595?source=see_link\">",
"       \"Patient information: Gallbladder cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy. Only a minority of patients are eligible for curative intent surgery because of local invasion into critical structures or metastases beyond locoregional confines. In these situations, treatment is palliative in nature. The goals of palliation for advanced GBC (as for other pancreaticobiliary cancers) are relief of pain, jaundice, and bowel obstruction, and prolongation of life. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Locoregionally advanced unresectable disease with or without obvious metastatic disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to its rarity, management protocols for locally advanced unresectable but nonmetastatic GBC are commonly extrapolated from studies of tumors of the bile ducts (cholangiocarcinoma). Like cholangiocarcinoma, dissemination of GBC is thought to be mainly locoregional, and the two tumors are generally managed similarly with external beam RT when they are locoregionally advanced and unresectable, particularly if the patient is symptomatic. Tumor control is rarely achieved with RT alone, and most patients receive external beam RT with concurrent 5-FU-based chemotherapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'RT with or without chemotherapy for locally advanced nonmetastatic disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=see_link\">",
"       \"Treatment options for locally advanced cholangiocarcinoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Guidelines from the National Comprehensive Cancer Network (NCCN) suggest 5-FU-based chemotherapy with radiation therapy, palliative chemotherapy, supportive care alone, or participation in a clinical trial as appropriate options for patients with an unresectable tumor without obvious metastatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although biliary or intestinal bypass can be considered for palliation of obstructive jaundice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/6\">",
"       6",
"      </a>",
"      ], stenting via an endoscopic or percutaneous approach is generally preferred, given the limited median survival in patients with advanced disease (generally, less than six months). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Palliation of obstructive jaundice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Systemic chemotherapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with locoregionally advanced unresectable GBC and those with distant metastatic disease who are able to tolerate it, palliative chemotherapy is an appropriate option. The optimal regimen has not been defined by randomized trials, and no single chemotherapy agent or combination regimen can be recommended for all patients as a standard of care at present. Guidelines from the NCCN suggest a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      5FU-based regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33977/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We prefer that patients enroll in clinical trials testing new agents or combinations, whenever possible. For patients who are not candidates for clinical trials or if they are not available, appropriate options for patients who can tolerate chemotherapy include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (CAPOX)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For initial therapy in patients with a good performance status, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with a borderline performance status, we suggest gemcitabine as a single agent (",
"      <a class=\"graphic graphic_table graphicRef60330 \" href=\"mobipreview.htm?35/56/36749\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34561?source=see_link\">",
"       \"Treatment protocols for hepatobiliary cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Supportive care alone is also an appropriate alternative.",
"     </li>",
"     <li>",
"      No regimen can be considered standard after failure of an initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based regimen. However, in patients who retain a good performance status we suggest an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen such as CAPOX or oxaliplatin plus short-term infusional 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34561?source=see_link\">",
"       \"Treatment protocols for hepatobiliary cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/1\">",
"      Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/2\">",
"      Hamrick RE Jr, Liner FJ, Hastings PR, Cohn I Jr. Primary carcinoma of the gallbladder. Ann Surg 1982; 195:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/3\">",
"      Yamaguchi K, Chijiiwa K, Ichimiya H, et al. Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch Surg 1996; 131:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/4\">",
"      A prospective analysis of 1518 laparoscopic cholecystectomies. The Southern Surgeons Club. N Engl J Med 1991; 324:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/5\">",
"      Kumaran V, Gulati S, Paul B, et al. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. Eur Radiol 2002; 12:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/6\">",
"      Kapoor VK, Pradeep R, Haribhakti SP, et al. Intrahepatic segment III cholangiojejunostomy in advanced carcinoma of the gallbladder. Br J Surg 1996; 83:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/7\">",
"      Saluja SS, Gulati M, Garg PK, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/8\">",
"      Pi&ntilde;ol V, Castells A, Bordas JM, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology 2002; 225:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/9\">",
"      Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/10\">",
"      Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/11\">",
"      Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/12\">",
"      Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/13\">",
"      Flickinger JC, Epstein AH, Iwatsuki S, et al. Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 1991; 68:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/14\">",
"      Houry S, Barrier A, Huguier M. Irradiation therapy for gallbladder carcinoma: recent advances. J Hepatobiliary Pancreat Surg 2001; 8:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/15\">",
"      Gunderson LL, Martin JK, O'Connell MJ, et al. Residual, recurrent, or unresectable gastrointestinal cancer. Role of radiation in single or combined modality treatment. Cancer 1985; 55:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/16\">",
"      Sasson AR, Hoffman JP, Ross E, et al. Trimodality therapy for advanced gallbladder cancer. Am Surg 2001; 67:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/17\">",
"      Uno T, Itami J, Aruga M, et al. Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor. Strahlenther Onkol 1996; 172:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/18\">",
"      Houry S, Schlienger M, Huguier M, et al. Gallbladder carcinoma: role of radiation therapy. Br J Surg 1989; 76:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/19\">",
"      Todoroki T. Radiation therapy for primary gallbladder cancer. Hepatogastroenterology 1997; 44:1229.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/21\">",
"      Eckel F, Brunner T, Jelic S, ESMO Guidelines Working Group. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 Suppl 6:vi40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/22\">",
"      Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001; 7:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/23\">",
"      Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/24\">",
"      Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/25\">",
"      Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 2005; 23:7753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/26\">",
"      Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28:4581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/27\">",
"      Kajanti M, Pyrh&ouml;nen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/28\">",
"      Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/29\">",
"      Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/30\">",
"      Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/31\">",
"      Gebbia V, Majello E, Testa A, et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 1996; 78:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/32\">",
"      Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/33\">",
"      Sanz-Altamira PM, Ferrante K, Jenkins RL, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/34\">",
"      Patt YZ, Jones DV Jr, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/35\">",
"      Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/36\">",
"      Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/37\">",
"      Chen JS, Jan YY, Lin YC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/38\">",
"      Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/39\">",
"      Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/40\">",
"      Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/41\">",
"      Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/42\">",
"      Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/43\">",
"      Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/44\">",
"      Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/45\">",
"      Cho JY, Nam JS, Park MS, et al. A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei Med J 2005; 46:526.",
"     </a>",
"    </li>",
"    <li>",
"     Iqbal S, McCoy H, Lenz HJ, et al. A Phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma (abstract). J Clin Oncol 2006; 24:211s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/47\">",
"      Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/48\">",
"      Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009; 101:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/49\">",
"      Julka PK, Puri T, Rath GK. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 2006; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/50\">",
"      Andr&eacute; T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/51\">",
"      Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/52\">",
"      Wagner AD, Buechner-Steudel P, Moehler M, et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009; 101:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/53\">",
"      Murad AM, Guimar&atilde;es RC, Arag&atilde;o BC, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 2003; 26:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/54\">",
"      Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/55\">",
"      Riechelmann RP, Townsley CA, Chin SN, et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/56\">",
"      Iyer RV, Gibbs J, Kuvshinoff B, et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 2007; 14:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/57\">",
"      Suzuki E, Furuse J, Ikeda M, et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010; 79:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/58\">",
"      Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19:4089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/59\">",
"      Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008; 53:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/60\">",
"      Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/61\">",
"      Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/62\">",
"      Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol 2010; 28:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/63\">",
"      Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007; 73:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/64\">",
"      Andr&eacute; T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/65\">",
"      Papakostas P, Kouroussis C, Androulakis N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/66\">",
"      Kuhn R, Hribaschek A, Eichelmann K, et al. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002; 20:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/67\">",
"      Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/68\">",
"      Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33977/abstract/69\">",
"      Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28:3491.",
"     </a>",
"    </li>",
"    <li>",
"     Ramanathan RK, Belani CP, Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC) (abstract). J Clin Oncol 2006; 24:180s.",
"    </li>",
"    <li>",
"     Sancho A, Lopez-Vivanco G, Diaz de Concuera I, et al. Oxaliplatin and capecitabine after gemcitabine failure in patients with advanced, pancreatic, biliary, and gallbladder adenocarcinoma (abstract). J Clin oncol 2008; 26:665s.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at www.nccn.org (Accessed on October 12, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2499 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33977=[""].join("\n");
var outline_f33_11_33977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PALLIATION OF OBSTRUCTIVE JAUNDICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RT WITH OR WITHOUT CHEMOTHERAPY FOR LOCALLY ADVANCED NONMETASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      5-FU-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Infusional 5-FU plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Leucovorin-modulated 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Capecitabine with and without oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gemcitabine and gemcitabine-based combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gemcitabine plus 5-FU and leucovorin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gemcitabine plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gemcitabine plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gemcitabine plus carboplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gemcitabine plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Gemcitabine plus oxaliplatin and 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169426\">",
"      - Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169387\">",
"      - Erlotinib plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5864415\">",
"      - GEMOX plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3169440\">",
"      - Lapatanib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SECOND-LINE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Locoregionally advanced unresectable disease with or without obvious metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2499|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/36/582\" title=\"figure 1\">",
"      Bismuth-Corlette classification of biliary tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 1\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/56/36749\" title=\"table 2\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43399?source=related_link\">",
"      Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/31/4595?source=related_link\">",
"      Patient information: Gallbladder cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34561?source=related_link\">",
"      Treatment protocols for hepatobiliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33978="Neurologic manifestations of systemic lupus erythematosus";
var content_f33_11_33978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Shahram Khoshbin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/11/33978/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/11/33978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14540273\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic and psychiatric symptoms are reported to occur in 10 to 80 percent of patients either prior to the diagnosis of systemic lupus erythematosus (SLE) or during the course of their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The wide range in reported prevalence reflects in part the use of different criteria for neuropsychiatric disease. Similarly the reported frequencies of individual neurologic and psychiatric manifestations also vary widely, depending in part upon the population studied, the case definition used, and methods used for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Rheumatology (ACR) has formulated case definitions, reporting standards, and diagnostic testing recommendations for 19 neuropsychiatric SLE syndromes (",
"    <a class=\"graphic graphic_table graphicRef51238 \" href=\"mobipreview.htm?6/40/6796\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/9\">",
"     9",
"    </a>",
"    ]. The full definitions can be found at the following Internet address:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/publications/ar/1999/aprilappendix.asp?aud=mem\">",
"     www.rheumatology.org/publications/ar/1999/aprilappendix.asp?aud=mem",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The frequency of neuropsychiatric symptoms appears to be increasing because of both better testing and increased clinician awareness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/2\">",
"     2",
"    </a>",
"    ]. The neuropsychiatric manifestations of SLE are varied and may be classified as primary neurologic and psychiatric disease (eg, related to direct involvement of the neuropsychiatric system) or secondary disease (eg, related to complications of the disease and its treatment) (",
"    <a class=\"graphic graphic_table graphicRef63649 \" href=\"mobipreview.htm?17/40/18061\">",
"     table 2",
"    </a>",
"    ). The latter are generally more common causes of neuropsychiatric symptoms and can be produced by a variety of mechanisms (",
"    <a class=\"graphic graphic_table graphicRef81577 \" href=\"mobipreview.htm?21/44/22220\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic discusses the pathophysiology, clinical manifestations, diagnosis, and treatment of neurologic manifestations of SLE. The diagnostic approach to patients with neuropsychiatric manifestations is presented separately. Other clinical manifestations of SLE are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=see_link\">",
"     \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE may affect the nervous system at multiple levels, with differing neuropathology. Identification of these diverse pathophysiologic mechanisms has helped to uncover possible mechanisms of immune-mediated neuropsychiatric disorders and has permitted more accurate and effective therapy. For the purposes of this discussion, the term lupus cerebritis is used to refer to the neuropsychiatric manifestations of lupus that appear to have an organic basis, rather than a specific pathophysiologic mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nervous system involvement in SLE was initially thought to be due to vasculitis. This idea was challenged, however, by investigators who found that true vasculitis was a rare finding in patients with SLE and neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/10\">",
"     10",
"    </a>",
"    ]. However, many patients may have a vasculopathy that may cause direct injury and can also affect the blood-brain barrier, thereby allowing antibodies to enter the nervous system. This vasculopathy is characterized by a small to moderate perivascular accumulation of mononuclear cells, without destruction (eg, fibrinoid necrosis) of the blood vessel. There may be small infarcts due to luminal occlusion.",
"   </p>",
"   <p>",
"    The pathogenesis of the vasculopathy and the vasculitis are not known. Certain autoantibodies have been associated with different aspects of CNS lupus but not with the vascular disease itself. Antiphospholipid antibodies may play a role in the vasculopathy in at least some patients, since they have been associated with stroke syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accelerated atherosclerosis may contribute to the risk of stroke in patients with SLE. The risk factors for arterial changes that are used as surrogates for pathologic changes in medium and large arteries, namely the presence of plaque, stenosis, and increased intimal-media thickness, may differ in the carotid arteries versus the aorta. This was illustrated in a study of 214 women with SLE whose carotid arteries and proximal aorta were assessed using B-mode and Doppler ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/11\">",
"     11",
"    </a>",
"    ]. The major observations were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of plaque was associated with older age, higher systolic blood pressure, lower levels of high-density lipoprotein (HDL)-3, antidepressant use, lower levels of albumin, and cigarette smoking.",
"     </li>",
"     <li>",
"      Increased intimal-medial wall thickness was associated with older age, higher pulse pressure, lower levels of albumin, elevated CRP, and high levels of cholesterol and glucose.",
"     </li>",
"     <li>",
"      Increased aortic stiffness was associated with older age, higher systolic blood pressure, higher complement component 3 (C3) levels, lower white blood cell count, higher insulin levels, and the presence of renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the risk factors for arterial disease listed above have also been suggested to be risk factors for coronary heart disease in patients with SLE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration of a number of autoantibodies in patients with SLE has focused attention on the possible association between nervous system involvement and the presence of specific antibodies. The following observations are compatible with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineuronal antibodies targeted to human neuroblastoma cells were found in one report in 45 percent of patients with CNS lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/12\">",
"       12",
"      </a>",
"      ]. By contrast, these antibodies are detectable in only 5 percent of patients with SLE who did not have nervous system involvement. Other antineuronal antibodies have been detected, including those with glycolipid specificity, those with high concentrations in the CSF, and those associated with seizures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive dysfunction has been associated with lymphocytotoxic antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies appear to increase the risk of stroke syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/16\">",
"       16",
"      </a>",
"      ], appear to increase the risk of recurrent seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/17\">",
"       17",
"      </a>",
"      ], and are associated with an increased prevalence of abnormal findings on magnetic resonance imaging (MRI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiribosomal P protein antibodies have been suggested by some authors to be associated with lupus psychosis and depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/19\">",
"       19",
"      </a>",
"      ] but not with cognitive dysfunction or psychologic distress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/20\">",
"       20",
"      </a>",
"      ]. Others have not confirmed the association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27718?source=see_link\">",
"       \"Antiribosomal P protein antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One study found high levels of autoantibodies to a 50 kDa antigen located in the plasma membrane of brain synaptic terminals in 19 of 20 patients with SLE who had CNS involvement. Low levels were present in 35 percent of SLE patients without CNS involvement, and this antibody was not detected in normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-endothelial-cell antibodies may be associated with psychiatric manifestations in SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13\">",
"       13",
"      </a>",
"      ]. Elevated levels of antibodies that target the C-terminal region of Nedd5, an intracytoplasmic protein of the septin family found in endothelial cells, have been associated with psychosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/22\">",
"       22",
"      </a>",
"      ]. On the other hand, cerebrovascular endothelial dysfunction was not present in the majority of patients with SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cross-reacting antibodies have been found in the serum and cerebrospinal fluid of patients that are able to bind double stranded DNA and excitatory N-methyl-D-aspartate receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/24\">",
"       24",
"      </a>",
"      ]. These human antibodies are neurotoxic both in vitro and, in a rodent model, in vivo.",
"     </li>",
"     <li>",
"      Lymphocytotoxic antibodies were found in 35 of 59 patients (59 percent) with active SLE versus 4 of 30 patients (13 percent) with inactive SLE, irrespective of whether they had NPSLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other specificities that have demonstrated variable associations with NPSLE include anti-ganglioside Ab, anti-neurofilament Ab, anti-glial fibrillary acidic protein Ab, anti-Nedd5 Ab, anti-triosephosphate antibody,",
"      <span class=\"nowrap\">",
"       anti-SSA/Ro,",
"      </span>",
"      Anti-Sm, anti-histone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13\">",
"       13",
"      </a>",
"      ], anti-alpha-internexin Ab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The roles, if any, of antineuronal, antineural tissue-specific, and anti-N-methyl-D-aspartate receptor (NMDA) antibodies are uncertain. Antibodies with these specificities are found in patients with many neuropsychiatric manifestations, including organic brain syndromes, cognitive dysfunction, and depression, but studies of associations with specific deficits or mood disorders have been inconclusive or have reached disparate conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13,21,27-34\">",
"     13,21,27-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14539089\">",
"    <span class=\"h2\">",
"     Secondary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies suggest that from 50 to 78 percent of neurologic episodes are caused by secondary factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/2,35\">",
"     2,35",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections associated with immunosuppressive therapy",
"     </li>",
"     <li>",
"      Metabolic complications of other organ system failure, such as uremia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Toxic effects of therapy (particularly corticosteroids)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional challenge in patients with SLE is to determine whether neurologic symptoms are functional (ie, have a psychologic basis) or are due to an organic abnormality (ie, are due to dysfunction of the central or peripheral nervous system) and, if the basis is organic, whether the symptoms or findings are due to lupus itself (either active or inactive) or are due to other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors other than vascular disease and autoantibodies may contribute to nerve injury and CNS lupus. These include cytokines, chemokines, APRIL, BAFF, neuropeptides, oxidative stress, nitric oxide, and interference with neurotransmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic heterogeneity may also contribute to the diverse neurologic complications associated with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMMON CLINICAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common neurologic manifestations of SLE are cognitive dysfunction, stroke, seizures, headaches, and peripheral neuropathy. This section will review these disorders and will present a general approach to therapy of the individual conditions. Treatment tends to vary with the manifestation. As examples, stroke due to antiphospholipid antibodies is treated with anticoagulants, and cognitive defects may respond to steroids, antidepressants,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiolytics. The possible role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and plasmapheresis in certain settings is discussed separately at the end of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cognitive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction, manifested by impairments in mental activities (eg, memory, abstract thinking, and judgment), is very prevalent among patients with SLE. When a battery of neuropsychological tests is used to assess cognitive function, deficits may be present in 20 to 80 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=see_link&amp;anchor=H5#H5\">",
"     \"Neuropsychiatric manifestations of systemic lupus erythematosus\", section on 'Cognitive defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stroke syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE may be associated with a significant increase in the risk of stroke and of premature death due to cerebrovascular disease. Strokes have been reported in up to 19 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. An analysis of hospital discharges for young patients with stroke revealed that SLE is a risk factor for stroke with an age and sex adjusted odds ratio of 1.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/43\">",
"     43",
"    </a>",
"    ]. Among patients with SLE, baseline disease activity, hyperlipidemia, and hypertension are risk factors for stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strokes in the setting of SLE may be particularly severe. In a prospective cohort of patients with SLE, a high proportion, 77 percent, of incident strokes were associated with an NIH stroke scale of &gt;6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complement deposition on platelets may be a marker for neuropsychiatric lupus and stroke syndromes in SLE. As an example, a positive correlation has been noted between surface complement component C4d and the severity of acute ischemic stroke as measured by NIH stroke scale and Infarct volume as determined by MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another observational study of 2688 Canadian patients with SLE, the risk of death due to stroke or other cerebrovascular disease was doubled when compared with non-SLE controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the prognosis of patients with SLE hospitalized with stroke does not appear to be substantially different than that of non-SLE patients; fatality rates were 12.3 percent for both groups in the hospital-based study cited earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our experience with 120 patients seen between 1978 and 1985 revealed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 7 percent had a stroke syndrome, either in the form of a transient ischemic attack (TIA) or ischemic brain infarction.",
"     </li>",
"     <li>",
"      Most strokes occurred within the first five years of illness.",
"     </li>",
"     <li>",
"      Recurrent strokes were common.",
"     </li>",
"     <li>",
"      There was a strong association between the occurrence of a stroke syndrome and the presence of other thrombotic episodes and antiphospholipid antibodies.",
"     </li>",
"     <li>",
"      Autopsy studies found both small vessel disease and large vessel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other reports in the literature also report a high association between antiphospholipid antibodies and stroke in SLE patients. One study, for example, evaluated 96 patients with SLE and CNS manifestations (primarily stroke, transient ischemic attack, and seizures) that were not attributable to any cause other than SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/16\">",
"     16",
"    </a>",
"    ]. Antiphospholipid antibodies were present in 55 versus 20 percent in a control group with SLE and no CNS or thromboembolic disease. Only about one-half of these patients had evidence of active lupus at the onset of CNS disease. Antiphospholipid antibodies (aPL) were primarily associated with small high-intensity white matter lesions on MRI that were suggestive of vasculopathy.",
"   </p>",
"   <p>",
"    The presence of persistent elevated aPL antibodies of different specificities may increase the risk of stroke more than a single aPL does. This was illustrated in a study of 125 patients with SLE, 35 of whom developed a cerebral infarction; the presence of a combination of",
"    <span class=\"nowrap\">",
"     anti-cardiolipin/beta2-gylcoprotein",
"    </span>",
"    I and",
"    <span class=\"nowrap\">",
"     anti-phosphatidylserine/prothrombin",
"    </span>",
"    antibodies was strongly associated with cerebral infarction, more so than a positive test for a lupus anticoagulant alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, the combination of these antibodies in vitro resulted in activation of platelets, which could contribute to a hypercoagulable state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other stroke subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to aPL, stroke syndromes have many other potential etiologies in SLE patients. As an example, hypertension and accelerated atherosclerosis, both associated with chronic steroid therapy, are common risk factors for stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/47\">",
"     47",
"    </a>",
"    ]. Elevated plasma homocysteine levels have been identified as a risk factor for stroke and other thrombotic events in patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/48\">",
"     48",
"    </a>",
"    ]. Other factors, such as infection, vasculitis, valvular heart disease, emboli,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis, can affect large or small blood vessels, thereby causing large vessel occlusive disease and infarction, or TIAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ]. Hemorrhagic stroke, due to intracerebral or subarachnoid bleeding, may also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/51\">",
"     51",
"    </a>",
"    ]. SLE is a risk factor for all stroke subtypes, except for subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large vessel disease may be due to coagulopathy, cardiogenic embolism, vasculitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      premature atherosclerosis. Patients with hypertension, a thrombotic thrombocytopenic purpura-like picture,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aPL are at particular risk for developing stroke with resulting hemiparesis, hemisensory loss, ocular field defects, or aphasia. One study evaluated 30 patients with symptomatic large vessel occlusive disease that was documented angiographically. The average age at stroke onset was 35 years, and at least 86 percent had active SLE at the time of their strokes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/47\">",
"       47",
"      </a>",
"      ]. The short-term death rate was 40 percent in this study, and the recurrent stroke rate was 13 percent.",
"     </li>",
"     <li>",
"      TIAs and recurrent small infarcts are the most common neurologic manifestations in patients with aPL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/16\">",
"       16",
"      </a>",
"      ]. In some cases, however, the combination of cognitive defects and an abnormal MRI is sometimes the first clue to the presence of aPL.",
"     </li>",
"     <li>",
"      CNS vasculitis due to SLE typically presents with a distinct syndrome of fever, severe headaches, and confusional episodes, with rapid progression to psychotic symptoms, seizures, and coma. Evidence of active lupus is usually demonstrable (eg, hypocomplementemia and elevated anti-DS-DNA antibody), and, in our experience, the MRI or MRA is abnormal, with focal defects. Other tests of neurologic function, if performed, are also usually abnormal. This includes electroencephalography (EEG), analysis of the cerebrospinal fluid, proton emission tomography (PET), single photon emission computed tomography (SPECT) scans, and conventional cerebral angiography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=see_link\">",
"       \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic anticoagulation therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is indicated in most patients with stroke syndromes due to aPL or thrombosis if they are stable and if there is no evidence of hemorrhage.",
"   </p>",
"   <p>",
"    A comparison of moderate intensity",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation (target INR of 1.8 to 2.4) to low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    found similar efficacy, and, thus, either could be considered for stroke prevention following an initial event. A panel of experts in the antiphospholipid syndrome could not reach a consensus on the optimal approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is uncertainty about the optimal approach to treatment of nonhemorrhagic strokes in patients with SLE, realizing the importance of carefully assessing the risks and potential benefits of a particular approach in an individual patient, the following are our recommendations for some common situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the patient with SLE and persistent elevation of aPL and with no stroke events, low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      81",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is recommended. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of the antiphospholipid syndrome\", section on 'SLE with aPL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the patient with SLE and an ischemic stroke who has no other identifiable risk factors (eg, does not have atrial fibrillation, has no vegetations by echocardiography, has no significant extracranial arterial stenosis, has no aPL) and for whom MRI suggests small vessel thrombosis, we recommend use of low-dose (81",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For the patient with SLE and moderate or high levels of aPL, we recommend anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with an INR target of 2 to 3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of glucocorticoids and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H35\">",
"     'Cyclophosphamide'",
"    </a>",
"    below) may be warranted if there is an associated lupus flare (including active vasculitis). By contrast, steroids are not used in patients with a stroke and aPL who have no evidence of active lupus. Steroid therapy is usually ineffective in this setting and may be associated with significant side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures develop in approximately 10 to 20 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/17,53,54\">",
"     17,53,54",
"    </a>",
"    ]. Both generalized and partial seizures can occur. The latter may be complex (complex partial seizures) or simple (focal epilepsy). Seizures may be the first manifestation of lupus or may develop during the course of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/5\">",
"     5",
"    </a>",
"    ]. In one case series, about half of new-onset seizures occurred during the first year after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of seizures are varied and may reflect an acute inflammatory episode or old CNS damage with scarring. Other factors may also contribute including aPL, metabolic disturbances (such as uremia), hypertension, infections, tumors, head trauma, stroke, medication withdrawal, vasculopathy, or drug toxicity (eg, high doses of antimalarials, nitrogen mustard) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/49,54,55\">",
"     49,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk of seizures has been associated with anti-50 kDa, anti-Sm, and aPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/21,53,56\">",
"     21,53,56",
"    </a>",
"    ]. Other risk factors may include concomitant neuropsychiatric symptoms and other evidence of high disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/53\">",
"     53",
"    </a>",
"    ]. Seizure recurrence may be more likely in those who have aPL as well as a history of stroke, other neurologic complications of SLE, and higher disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/17,53\">",
"     17,53",
"    </a>",
"    ]. Seizures tend to occur early in the course of SLE and, thus, affect younger patients with high disease activity. The presence of anti-La autoantibody and antimalarial use has been associated with lower risk of seizure occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of focal seizures in the absence of a clear etiology, with negative angiograms, CT, and MRI, is probably due to a local vasculopathy, as described above. Vasculitis alone infrequently causes seizures, since CNS vasculitis, in the absence of systemic vasculitis or other manifestations of active lupus, is a rarely documented event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We have seen either generalized or partial seizures in 25 percent of our patients with SLE. Complex partial seizures were more common than primary generalized seizures, although the later tended to be more common in patients with lupus nephritis and hypertension. Complex partial seizures were often seen as the initial manifestation of SLE and strongly correlated with the presence of psychosis (characterized by paranoid ideation) and focal electroencephalographic abnormalities, particularity in the temporal lobe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized clinical trials that have specifically examined the treatment of seizures in patients with SLE. A variety of antiepileptic medications can be used depending upon the type of seizures. The evaluation and management of seizures in the setting of SLE does not differ from that in the general clinical setting. A general overview of the evaluation and treatment of seizure disorders is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiepileptic drug (AED) therapy may not be necessary in patients with single or infrequent seizures, unless high-risk features for recurrence are present, such as two or more unprovoked seizures occurring within 24 hours, serious brain injury, brain MRI structural abnormalities causally linked to seizures, focal neurological signs, partial seizure, and epileptiform EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of epilepsy in adults\", section on 'When to start AED therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations have been made in series of patients with seizures and SLE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case series of 75 patients with new-onset seizures in the setting of SLE, seizure recurrence occurred in 40. Eighteen patients required a second AED to control seizure activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While there are case reports of drug-induced SLE in which the drug was an AED (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ), an alternative explanation in at least some of these cases is that the seizure was the first sign of SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/10\">",
"       10",
"      </a>",
"      ]. We do not avoid these medications in patients with SLE.",
"     </li>",
"     <li>",
"      If new onset seizures are thought to reflect an acute inflammatory event or if a concomitant flare exists, a short course of steroids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses) may be given in an attempt to prevent the development of a permanent epileptic focus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of pulse intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was effective in reducing seizure frequency in a case series of patients with refractory seizures and SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is relatively common in patients with SLE, but there does not appear to be a causal relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/51,63\">",
"     51,63",
"    </a>",
"    ]. A pooled analysis of data from eight controlled and uncontrolled studies that used the International Headache Society (IHS) criteria for diagnosis found that 57.1 percent of patients with SLE reported any type of headache (31.7 percent migraine, 23.5 percent tension), but the prevalence of all headache types was not different from controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/64\">",
"     64",
"    </a>",
"    ]. No particular pathogenetic mechanism of headache was identified, nor was there an association between headache and the disease status, clinical features including central nervous system involvement, or autoantibodies including antiphospholipid antibodies.",
"   </p>",
"   <p>",
"    Thus, headache alone in a patient with SLE does not require additional investigation beyond the evaluation that would be performed for a patient with headache who does not have SLE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .) Migraine and tension headache are most common, although other rarer disorders should be considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"mobipreview.htm?40/58/41899\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/51\">",
"     51",
"    </a>",
"    ]. An organic basis for the headaches is suggested by the sudden development in someone previously free of headaches, associated with neurologic changes or changes in personality.",
"   </p>",
"   <p>",
"    The treatment of headaches in patients with SLE does not differ from that in patients without this disease unless there are other manifestations of CNS lupus as noted above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link\">",
"     \"Headache syndromes other than migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14539199\">",
"    <span class=\"h2\">",
"     Psychiatric aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychiatric aspects of this disorder, including anxiety, cognitive dysfunction, mood disorders, and psychosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=see_link\">",
"     \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of patients with SLE develop a peripheral neuropathy that is probably due to vasculopathy of small arteries supplying the affected nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/65\">",
"     65",
"    </a>",
"    ]. Autonomic neuropathy has also been reported in some patients, resulting in multiple gastrointestinal, bladder, cardiac, pupillary, and sweating abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral neuropathy due to SLE is usually asymmetric, mild, is may affect more than one nerve (polyneuropathy or mononeuritis multiplex), and affects sensory nerves more than motor nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ]. A typical presentation may be that of bilateral (but not truly symmetric) paresthesias and numbness of the digits that are often worse at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/63\">",
"     63",
"    </a>",
"    ]. A small-fiber neuropathy may also occur in SLE, producing painful sensory symptoms in the absence of abnormalities on nerve conduction studies or reflex changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. This may be isolated or may coexist with large-fiber polyneuropathy.",
"   </p>",
"   <p>",
"    In our series of 120 patients with SLE, peripheral neuropathy was a common manifestation. Ten percent presented with numbness or paresthesias in cutaneous nerves of the arms, suggestive of mononeuritis multiplex involving the upper extremity. Generalized sensorimotor peripheral neuropathy was also noted with electromyographic and nerve conduction abnormalities, suggesting axonal degeneration. In contrast with seizures, peripheral neuropathy does not typically occur early in the course of SLE.",
"   </p>",
"   <p>",
"    Inflammatory polyradiculoneuropathy, including the acute form resembling Guillain-Barr&eacute; syndrome and the chronic form resembling chronic inflammatory demyelinating polyradiculoneuropathy (CIPD), has been observed in patients with SLE in a few case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the acute form present with sudden onset of ascending areflexic motor weakness with no sensory loss. Such patients respond to glucocorticoids within weeks if there has been no neuronal damage. SLE patients with CIPD may present with recurrent episodes of Guillain-Barr&eacute; syndrome-like symptoms, mononeuritis multiplex, or symmetric polyradiculopathy over a period of weeks to months. Therapy with glucocorticoids and intravenous gamma globulin or plasmapheresis may be indicated. If there is evidence of axonal damage on electrodiagnostic studies or vasculitis on nerve biopsy, then more potent immunosuppressive therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathies generally respond to therapy with glucocorticoids in moderate to higher doses (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 to 60",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    but not all patients improve. As an example, of 20 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/63\">",
"     63",
"    </a>",
"    ] reassessed after seven years, nerve conduction velocity deteriorated in one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/71\">",
"     71",
"    </a>",
"    ]. No correlation between peripheral nerve function and drug therapy was evident.",
"   </p>",
"   <p>",
"    A complete response may take weeks to months to be clinically apparent, because of the slow pace of nerve regeneration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is pain or intolerable paresthesia and if a nerve conduction test is abnormal, we recommend glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or equivalent) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (initial dose of 100 mg three times daily) or a low dose of a tricyclic antidepressant such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (initial dose 25",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    If either of these approaches is ineffective or causes intolerable side effects, we would next utilize",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Active vasculitic neuropathy (eg, mononeuritis multiplex) warrants use of glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    or equivalent) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy (either oral daily intake at a starting dose of 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    or intermittent monthly intravenous doses of 600 to 750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    with or without plasma exchange for a six-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the nerve conduction test shows no abnormalities, then we do not use glucocorticoids for neuropathy and would initiate either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or low-dose tricyclic antidepressants as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     UNCOMMON NEUROLOGIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE less commonly presents with movement disorders, cranial neuropathies, and eye involvement and rarely presents with transverse myelitis and meningitis. These are discussed in more detail below. Other rare disorders include the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), hyperprolactinemia, sensorineural hearing loss, and brainstem and cerebellar syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Movement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Movement disorders occur in less than 5 percent of patients. Symptoms may include chorea, ataxia, choreoathetosis, dystonia, and hemiballismus. Dopamine-resistant parkinsonism has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/5\">",
"     5",
"    </a>",
"    ]. Movement disorders usually occur with other associated signs of active organic brain involvement rather than as an isolated feature.",
"   </p>",
"   <p>",
"    Movement abnormalities are thought to reflect lesions in the cerebellum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basal ganglia. Brain imaging should be considered when other focal neurological signs are present or to exclude secondary causes of chorea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ]. Some association with antiphospholipid antibodies has been made, raising the question of whether these patients should be treated with anticoagulant or antiplatelet therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61,73,74\">",
"     61,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of corticosteroids and other immunosuppressive therapy has also been advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61,75\">",
"     61,75",
"    </a>",
"    ]. In our experience, however, this is a self-limited and reversible disorder and, therefore, may not require therapy. As an example, we have seen three cases of chorea, each of which resolved within two to six weeks without any specific treatment. Symptomatic therapy with dopamine antagonists or other agents can be effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=see_link&amp;anchor=H12#H12\">",
"     \"Huntington disease: Management\", section on 'Choosing interventions for chorea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cranial neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial nerve involvement is usually associated with other manifestations of active SLE. Depending upon the location of the neuropathy, symptoms may include diplopia, nystagmus, ptosis, visual field deficits, trigeminal neuralgia, dysarthria, facial weakness, and vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye movement abnormalities are seen infrequently and are usually transitory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Optic neuritis in SLE is frequently bilateral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/77-79\">",
"       77-79",
"      </a>",
"      ]. The underlying mechanism may vary along with the acuity of its presentation. Testing reveals antiphospholipid antibodies, optic nerve enhancement on MRI, and other MRI abnormalities in a high proportion.",
"     </li>",
"     <li>",
"      Sensorineural hearing defects in both low and high frequencies have been noted more frequently in patients with SLE than in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although rare, the presence of cranial neuropathies in patients with SLE must be differentiated from multiple sclerosis (MS), brainstem stroke, and meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ]. Optic neuritis, internuclear ophthalmoplegia, and transverse myelitis all occur in both conditions. The term &ldquo;lupoid sclerosis&rdquo; has been given to patients who have MRI abnormalities that are similar to the findings in MS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75730 \" href=\"mobipreview.htm?22/9/22687\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. If not previously tested, patients with lupus and cranial neuropathies should be assessed for the presence of antiphospholipid antibodies, concurrent Lyme disease, sarcoidosis, myasthenia gravis, and mid-brain or base-of-skull lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to treating cranial neuropathies is uncertain. Glucocorticoids are generally used first (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has generally been reserved for those who do not respond to glucocorticoids. The possible value of this approach was illustrated in a small uncontrolled series of 10 Mexican patients with SLE and bilateral optic nerve involvement who had visual impairment that was refractory to steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/83\">",
"     83",
"    </a>",
"    ]. Intravenous cyclophosphamide (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was given monthly for six months. Complete recovery of vision occurred in 50 percent of affected eyes, partial recovery in 30 percent, and no improvement in acuity in 20 percent. Other case series also support an aggressive treatment of optic neuritis with combined glucocorticoids and cyclophosphamide approach in patients with optic neuritis and SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/62,84\">",
"     62,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally begin treatment of cranial neuropathies with glucocorticoids in a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or equivalent), and we would consider adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    if visual loss was due to optic nerve involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Eye involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye involvement is relatively common in SLE and can involve the lids, conjunctiva, globe, and uvea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye lids may be involved by discoid disease of the skin.",
"     </li>",
"     <li>",
"      Mild keratoconjunctivitis sicca occurs in 25 to 35 percent of patients. This is typically associated with symptoms such as a foreign body sensation and itching. Other symptoms include a sense of heaviness of the eyelids or a red eye. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\", section on 'Keratoconjunctivitis sicca'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other manifestations of anterior segment ocular involvement include anterior uveitis (iritis), keratitis, and episcleritis. These are most often manifest by photophobia, pain, and sometimes decreased vision.",
"     </li>",
"     <li>",
"      Posterior segment involvement includes retinal vasculopathy and vasculitis. Retinal vascular disease, responding to treatment with glucocorticoids, is not uncommon, while true vasculitis is rare. Retinal vasculopathy is often accompanied by other evidence of CNS lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/87\">",
"       87",
"      </a>",
"      ]. The most characteristic finding of retinal disease is the presence of cotton wool exudates (cytoid bodies) (",
"      <a class=\"graphic graphic_picture graphicRef67621 graphicRef50474 \" href=\"mobipreview.htm?2/17/2322\">",
"       picture 1A-B",
"      </a>",
"      ). These are usually near the disc and reflect microangiopathy of the retinal capillaries and localized microinfarction of the superficial nerve fiber layers of the retina. While older studies reported that cytoid bodies were found in 10 to 25 percent of patients in association with other manifestations of active lupus, these lesions are rarely seen in current practice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/88\">",
"       88",
"      </a>",
"      ]. The presence of microaneurysms on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      dye angiography indicates retinal vasculitis. Retinal vascular occlusion caused by vasculitis or related to antiphospholipid antibodies is rare, but it may cause significant visual loss and has a poor response to therapy.",
"     </li>",
"     <li>",
"      Autoimmune retinopathy has been reported in SLE. In one case, multiple depigmented lesions in the peripheral retina and choroid and scattered pigmentary bone-spickling at the equator and periphery were seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/89\">",
"       89",
"      </a>",
"      ]. Peripheral retinal vessels were sclerotic and occluded, some surrounded by pigment granules and RPE cells. Cobblestone degeneration was prominent in the periphery. Serum autoantibodies against normal retinal nuclei were detected.",
"     </li>",
"     <li>",
"      Choroidopathy is less common than retinopathy but may occur in severely affected patients.",
"     </li>",
"     <li>",
"      Involvement of the optic nerve has been reported in small case series. This can present as papillitis, ischemic optic neuropathy, or retrobulbar optic neuritis, typically causing variable degree of visual loss. Response to treatment is variable. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cranial neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ocular symptoms may also occur as a complication of treatment. Glucocorticoid therapy may exacerbate or cause glaucoma and cataract formation and may predispose to infection of the eye. A fibrinous exudative retinal detachment may complicate systemic glucocorticoid use and may be confused with retinal vasculitis or posterior uveitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Eye'",
"    </a>",
"    .) Corneal and retinal side-effects of antimalarial drugs may also occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H12#H12\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, extreme caution should be used when considering corneal excimer laser ablation for the correction of refractive error in patients with SLE or other connective tissue diseases. Although several reports have demonstrated an absence of surgical complications after successful laser-in situ keratomileusis (LASIK surgery) in patients with inactive rheumatological disease, stromal haze, melting, ulceration, and poor wound healing following surgery have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapeutic agents have been used to treat retinal vasculopathy and vasculitis. In one retrospective study of nine patients, for example, various combinations of corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , and cytotoxic agents were found to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/93\">",
"     93",
"    </a>",
"    ]. The long-term use of cytotoxic agents was associated with a corticosteroid-sparing effect.",
"   </p>",
"   <p>",
"    Treatment of symptoms of ocular dryness in patients with SLE is similar to that of patients with Sj&ouml;gren's syndrome and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=see_link&amp;anchor=H26015999#H26015999\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Transverse myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis has been noted in patients presenting with the sudden onset of lower extremity weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory loss, plus loss of rectal and urinary bladder sphincter control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/94\">",
"     94",
"    </a>",
"    ]. While symptoms of transverse myelitis may be the initial feature of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/95\">",
"     95",
"    </a>",
"    ], the onset usually coincides with other signs of active lupus, including optic neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome is thought to be due to an arteritis, with resultant ischemic necrosis of the spinal cord. It has been associated with antiphospholipid antibodies in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/96\">",
"     96",
"    </a>",
"    ], but other series found no difference in the incidence of antiphospholipid antibodies in patients with or without transverse myelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/94\">",
"     94",
"    </a>",
"    ]. Myelopathy can also be due to hematomas, tumors, fractures, disc herniations, infections, vascular occlusions, demyelinating conditions, or epidural abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI should be performed to exclude a compressive lesion from infection or another cause. Patients with transverse myelitis and SLE may have localized edema along with T2 hyperintense foci on MRI scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61,97\">",
"     61,97",
"    </a>",
"    ]. CSF should be obtained to exclude infection; in SLE, there is typically an elevated protein level and a moderate lymphocytic pleocytosis.",
"   </p>",
"   <p>",
"    Recurrence of myelopathy in particular within the first year is common, especially during steroid dose reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While neuromyelitis optica (NMO) spectrum disorders (transverse myelitis occurring with bilateral optic neuritis) with seropositive findings for NMO-IgG have been described as occurring in SLE and antiphospholipid syndrome, investigations suggest their presence to be an indication of coexisting NMO rather than a vasculopathic or other complication of SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61,98\">",
"     61,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis must be treated aggressively and quickly if there is to be significant recovery. We and others have had success in a limited number of patients with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), plasmapheresis, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61,94,96,99\">",
"     61,94,96,99",
"    </a>",
"    ]. In a review of 105 patients, 50 and 29 percent had complete and partial recovery, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In those with transverse myelitis who have antiphospholipid antibodies, a good outcome may be achieved by combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with glucocorticoids and immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Central nervous system manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis may develop due to bacterial infection. A lumbar puncture and testing of the CSF is generally indicated if meningitis is suspected. Based upon the results of the lumbar puncture, those with meningitis can be classified into suspected acute bacterial or suspected aseptic meningitis. If an imaging study (CT or MRI) is indicated prior to lumbar puncture, antibiotics should be started empirically prior to patient's departure for the study. The pretreatment evaluation and management of suspected acute bacterial meningitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with suspected bacterial meningitis (eg, positive Gram stain, cell count",
"      <span class=\"nowrap\">",
"       &gt;1000/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      glucose &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      antibiotics should be initiated promptly.",
"     </li>",
"     <li>",
"      Patients with probable aseptic meningitis include those with CSF findings of cell count",
"      <span class=\"nowrap\">",
"       &lt;500/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      &gt;50 percent CSF lymphocytes, protein &lt;80 to 100",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      normal glucose, and negative Gram stain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many causes of aseptic meningitis (",
"    <a class=\"graphic graphic_table graphicRef79745 \" href=\"mobipreview.htm?18/30/18925\">",
"     table 5",
"    </a>",
"    ). In SLE patients treated with immunosuppressive agents, opportunistic infections (eg, Listeria monocytogenes, reactivation of tuberculosis, and fungi, such as Cryptococcus) should be considered.",
"   </p>",
"   <p>",
"    Aseptic meningitis may be due to drugs used in treating SLE, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (and less commonly other NSAIDs, excluding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, some patients with SLE develop aseptic meningitis manifested by headache, nuchal rigidity, and a pleocytosis in the CSF, without any other apparent cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=see_link&amp;anchor=H26#H26\">",
"     \"Aseptic meningitis in adults\", section on 'Approach to the patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bacterial, viral, and other infectious causes of meningitis are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=see_link\">",
"     \"Aseptic meningitis in adults\"",
"    </a>",
"    .) Suspected drug-induced aseptic meningitis generally responds to withdrawal of the offending agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Reversible posterior leukoencephalopathy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE is among the inflammatory autoimmune disorders that are associated with the reversible posterior leukoencephalopathy syndrome (RPLS). Clinical manifestations include seizures, headache, visual disturbances, and altered mental status. Renal failure, hypertension, and immunosuppressive medications are believed to be risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the clinical features of neuropsychiatric lupus and RPLS can overlap, it is important to distinguish between these because treatment approaches differ. MRI is the most helpful diagnostic tool in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/100\">",
"     100",
"    </a>",
"    ]. In RPLS, MRI demonstrates characteristic vasogenic cerebral edema that is usually most predominant in the posterior cerebral hemisphere and does not respect a specific vascular territory. Diffusion-weighted MRI (DWI) can help distinguish between the vasogenic edema of RPLS and the cytotoxic edema more typical of lupus-related infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience and in anecdotal reports, certain systemic findings in patients with SLE have been associated with particular neurologic syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Livedo reticularis has been associated with antiphospholipid antibodies and an ischemic cerebrovascular disease (&ldquo;Sneddon's syndrome&rdquo;) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/101,102\">",
"       101,102",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CNS vasculitis and transverse myelitis have been associated with signs of peripheral vasculitis, such as Osler nodes and Janeway lesions.",
"     </li>",
"     <li>",
"      Peripheral neuropathies have been associated with unilateral limb swelling, Jaccoud's arthritis, and Raynaud phenomenon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     USE OF MORE AGGRESSIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has primarily emphasized the use of specific therapy for different forms of neurologic manifestations of SLE. This may or may not include the use of glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has also been evaluated in a limited number of studies in addition to the report described above in patients with transverse myelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A controlled trial of 32 patients with SLE and an acute onset of severe neurologic manifestations (seizures, optic neuritis, neuropathy, coma, brainstem disease, or transverse myelitis) compared intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/62\">",
"       62",
"      </a>",
"      ]. Patients were followed for two years; 18 of the 19 receiving cyclophosphamide and 7 of the 13 receiving methylprednisolone had at least a 20 percent improvement in a pertinent neurologic measure. This was the only controlled trial to compare these two therapies that was identified in a 2006 systematic review and was the basis for a conclusion that cyclophosphamide is more effective than IV methylprednisolone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Response to intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was assessed in 31 patients with severe neuropsychiatric lupus, 90 percent of whom had failed previous therapy with glucocorticoids and, in some cases, oral cytotoxic drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/104\">",
"       104",
"      </a>",
"      ]. Eight patients received plasmapheresis in addition to cyclophosphamide. Substantial improvement was seen in 61 percent, and partial improvement was seen in 29 percent.",
"     </li>",
"     <li>",
"      Weekly intravenous pulses of 500 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      produced a &ldquo;good&rdquo; response in 24 of 25 patients with neuropsychiatric lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/105\">",
"       105",
"      </a>",
"      ]. However, patients were followed for a mean of only 11 months.",
"     </li>",
"     <li>",
"      In an uncontrolled study, 60 patients were treated for neuropsychiatric manifestations; the 37 who received intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (200 to 400 mg per month) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      had more improvement in measures of cognitive function and neurophysiologic testing than did 23 patients treated with prednisolone alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/106\">",
"       106",
"      </a>",
"      ]. Unfortunately, symptoms recurred within a few months after discontinuation of cyclophosphamide therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although intravenous pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was more effective than intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    in the one trial that compared these two treatments for neurologic manifestations of SLE, the difference was small. Additional studies are needed before the role of cyclophosphamide in the management of CNS lupus can be well-defined.",
"   </p>",
"   <p>",
"    We consider the use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (at an initial dose of 500 mg per square meter of body surface area) in patients with the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or recent onset of neurologic symptoms, such as seizures or organic brain syndromes in the absence of another cause",
"     </li>",
"     <li>",
"      Evidence of active inflammation in the brain, such as increased cells and protein in the cerebrospinal fluid and brain swelling on MRI or CT scan",
"     </li>",
"     <li>",
"      Failure to respond to a one to two week course of high-dose oral glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in a dose of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or to pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil have been used as second-line immunosuppressive agents; good outcomes were noted in the reported cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/5,107,108\">",
"     5,107,108",
"    </a>",
"    ]. Intravenous immunoglobulin administration and plasmapheresis have also been used in SLE patients; however, their role in CNS lupus needs to be confirmed in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a B cell depleting monoclonal anti-CD20 antibody, was administered to 10 patients with neuropsychiatric SLE, who were unresponsive to immunosuppressive, plasma exchange,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunoadsorption therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/110\">",
"     110",
"    </a>",
"    ]. All patients showed clinical improvement, with remissions lasting 4 to 29 months. In six patients, improvements in either MRI or SPECT studies were also observed. Controlled studies are needed to determine the role of this therapy in SLE. Two cases of fatal progressive multifocal leukoencephalopathy in SLE patients treated with rituximab with other immunosuppressive therapies have been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link&amp;anchor=H334601#H334601\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stem cell transplantation was studied in a phase I study, in which seven patients received high-dose chemotherapy followed by autologous stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/11/33978/abstract/111\">",
"     111",
"    </a>",
"    ]. These individuals had active diffuse proliferative glomerulonephritis, cerebritis, myelitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasculitis despite six cycles of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . At a median follow-up of 25 months, all patients were free from signs of active lupus, and renal, cardiac, and pulmonary function and serologic markers had improved despite either no immunosuppression or small residual doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The proposed mechanism of action is a period free from memory T cell influence, during which maturation of new lymphocyte progenitors can occur without recruitment to anti-self activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27245977\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic and psychiatric symptoms occur in a significant proportion of patients either prior to the diagnosis of systemic lupus erythematosus (SLE) or during the course of their illness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of neurologic manifestations of SLE is uncertain. An autoimmune mechanism and a vasculopathy have been implicated in some. Secondary factors including infections associated with chronic immunosuppressive therapy, metabolic complications of other organ system failure (eg, uremia), hypertension, and toxic effects of immunosuppressive therapy may play a role in some cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive dysfunction, manifested by impairments in mental activities (eg, memory, abstract thinking, and judgment), is very prevalent among patients with SLE (20 to 80 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=see_link\">",
"       \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strokes have been reported in up to 19 percent of patients with SLE and may be particularly severe. Antiphospholipid antibodies are prevalent in patients with stroke and SLE. Stroke mechanisms are heterogenous in SLE and include arterial and venous thrombosis, cardiogenic embolism, and small vessel infarcts. Vasculitis is an unusual stroke mechanism in this setting. Chronic anticoagulation therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is indicated in most patients with ischemic stroke syndromes due to antiphospholipid antibodies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Stroke syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures develop in 10 to 20 percent of patients with SLE. The evaluation and management of seizures in the setting of SLE does not differ from that in the general clinical setting, except that glucocorticoids may be administered for seizures arising in the setting of an acute inflammatory event. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Headache is relatively common in patients with SLE, but there does not appear to be a causal relationship. Thus, headache alone in a patient with SLE does not require additional investigation beyond the evaluation that would be performed for a patient with headache who does not have SLE. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 10 to 15 percent of patients with SLE develop a peripheral neuropathy that is probably due to vasculopathy of small arteries supplying the affected nerves. Autonomic neuropathy has also been reported in some patients. Neuropathies generally respond to therapy with glucocorticoids in moderate to higher doses (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      30 to 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      but not all patients improve. A complete response may take weeks to months to be clinically apparent, because of the slow pace of nerve regeneration. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SLE also may experience less common disorders, including movement disorders, cranial neuropathies, and eye involvement and, rarely, transverse myelitis and meningitis. Other rare disorders include the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), hyperprolactinemia, sensorineural hearing loss, and brainstem and cerebellar syndromes. Treatment varies, depending upon the specific disease manifestations. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Uncommon neurologic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      has also been evaluated in a limited number of studies. We consider the use of intravenous cyclophosphamide in patients with failure to respond to a one week course of high-dose oral glucocorticoids or to pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , who exhibit acute or recent onset of severe neurologic symptoms such as refractory seizures or optic neuritis in the absence of another cause and evidence of active inflammation in the brain by neuroimaging and CSF evaluation. Other agents have also been used in some patients. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Use of more aggressive therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Cyclophosphamide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/1\">",
"      Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/2\">",
"      Wong KL, Woo EK, Yu YL, Wong RW. Neurological manifestations of systemic lupus erythematosus: a prospective study. Q J Med 1991; 81:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/3\">",
"      Bruyn GA. Controversies in lupus: nervous system involvement. Ann Rheum Dis 1995; 54:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/4\">",
"      Futrell N, Schultz LR, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 1992; 42:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/5\">",
"      Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology 2007; 69:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/6\">",
"      Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004; 13:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/7\">",
"      Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010; 28:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/8\">",
"      Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/9\">",
"      The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/10\">",
"      Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968; 47:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/11\">",
"      Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/12\">",
"      Wilson HA, Winfield JB, Lahita RG, Koffler D. Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum 1979; 22:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/13\">",
"      Colasanti T, Delunardo F, Margutti P, et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 2009; 212:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/14\">",
"      Bluestein HG, Zvaifler NJ. Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 1976; 57:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/15\">",
"      Bluestein HG. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1978; 75:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/16\">",
"      Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/17\">",
"      Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/18\">",
"      Cs&eacute;p&aacute;ny T, Bereczki D, Koll&aacute;r J, et al. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003; 250:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/19\">",
"      Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/20\">",
"      Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/21\">",
"      Hanson VG, Horowitz M, Rosenbluth D, et al. Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein. J Exp Med 1992; 176:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/22\">",
"      Valesini G, Alessandri C, Celestino D, Conti F. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann N Y Acad Sci 2006; 1069:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/23\">",
"      Davey R, Bamford J, Emery P. The role of endothelial dysfunction in the pathogenesis of neuropsychiatric systemic lupus erythematosus. Lupus 2010; 19:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/24\">",
"      DeGiorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/25\">",
"      Magalh&atilde;es MB, da Silva LM, Voltarelli JC, et al. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/26\">",
"      Lu XY, Chen XX, Huang LD, et al. Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS One 2010; 5:e11124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/27\">",
"      West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/28\">",
"      Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/29\">",
"      Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/30\">",
"      Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/31\">",
"      Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/32\">",
"      Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/33\">",
"      Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/34\">",
"      Steup-Beekman G, Steens S, van Buchem M, Huizinga T. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/35\">",
"      Hanly JG, Su L, Farewell V, et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009; 36:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/36\">",
"      Hanly JG. Neuropsychiatric lupus. Curr Rheumatol Rep 2001; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/37\">",
"      Lu XY, Zhu CQ, Qian J, et al. Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus 2010; 19:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/38\">",
"      George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10:R97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/39\">",
"      Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narv&aacute;ez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/40\">",
"      Bautista JF, Kelly JA, Harley JB, Gray-McGuire C. Addressing genetic heterogeneity in complex disease: finding seizure genes in systemic lupus erythematosus. Epilepsia 2008; 49:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/41\">",
"      Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989; 20:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/42\">",
"      Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007; 38:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/43\">",
"      Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 2005; 118:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/44\">",
"      Mehta N, Uchino K, Fakhran S, et al. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 2008; 39:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/45\">",
"      Bernatsky S, Clarke A, Gladman DD, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 2006; 15:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/46\">",
"      Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/47\">",
"      Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994; 44:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/48\">",
"      Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348:1120.",
"     </a>",
"    </li>",
"    <li>",
"     Liang MH, Karlson E. Neurologic manifestations of lupus. In: The Clinical Management of Systemic Lupus Erythematosus, 2nd, Schur PH (Ed), Lippincott, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/50\">",
"      Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005; 95:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/51\">",
"      Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/52\">",
"      Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003; 12:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/53\">",
"      Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005; 64:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/54\">",
"      Gonz&aacute;lez-Duarte A, Cant&uacute;-Brito CG, Ruano-Calder&oacute;n L, Garc&iacute;a-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008; 59:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/55\">",
"      Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/56\">",
"      Herranz MT, Rivier G, Khamashta MA, et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/57\">",
"      Andrade RM, Alarc&oacute;n GS, Gonz&aacute;lez LA, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008; 67:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/58\">",
"      Malik S, Bruner GR, Williams-Weese C, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus 2007; 16:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/59\">",
"      Ramsey-Goldman R, Alarc&oacute;n GS, McGwin G, et al. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. Lupus 2008; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/60\">",
"      Bryant GL, Weinblatt ME, Rumbaugh C, Coblyn JS. Cerebral vasculopathy: an analysis of sixteen cases. Semin Arthritis Rheum 1986; 15:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/61\">",
"      Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/62\">",
"      Barile-Fabris L, Ariza-Andraca R, Olgu&iacute;n-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/63\">",
"      Omdal R, Henriksen OA, Mellgren SI, Husby G. Peripheral neuropathy in systemic lupus erythematosus. Neurology 1991; 41:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/64\">",
"      Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain 2004; 127:1200.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestein HG. Neuropsychiatric disorders in systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Lahita RG (Ed), John Wiley and Sons, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/66\">",
"      Straub RH, Zeuner M, Lock G, et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/67\">",
"      G&oslash;ransson LG, Tjensvoll AB, Herigstad A, et al. Small-diameter nerve fiber neuropathy in systemic lupus erythematosus. Arch Neurol 2006; 63:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/68\">",
"      Tseng MT, Hsieh SC, Shun CT, et al. Skin denervation and cutaneous vasculitis in systemic lupus erythematosus. Brain 2006; 129:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/69\">",
"      Lewis M, Gibson T. Systemic lupus erythematous with recurrent Guillain-Barr&eacute;-like syndrome treated with intravenous immunoglobulins. Lupus 2003; 12:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/70\">",
"      Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum 2005; 35:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/71\">",
"      Omdal R, L&oslash;seth S, Torbergsen T, et al. Peripheral neuropathy in systemic lupus erythematosus--a longitudinal study. Acta Neurol Scand 2001; 103:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/72\">",
"      Martinez-Taboada VM, Alonso RB, Armona J, et al. Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Lupus 1996; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/73\">",
"      Asherson RA, Derksen RH, Harris EN, et al. Chorea in systemic lupus erythematosus and \"lupus-like\" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 1987; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/74\">",
"      Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/75\">",
"      Galanaud D, Dormont D, Marsault C, et al. Brain MRI in patients with past lupus-associated chorea. Stroke 2000; 31:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/76\">",
"      Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol 1995; 52:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/77\">",
"      Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/78\">",
"      Jabs DA, Miller NR, Newman SA, et al. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 1986; 104:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/79\">",
"      Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999; 18:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/80\">",
"      Andonopoulos AP, Naxakis S, Goumas P, Lygatsikas C. Sensorineural hearing disorders in systemic lupus erythematosus. A controlled study. Clin Exp Rheumatol 1995; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/81\">",
"      Harris EN, Gharavi AE, Mackworth-Young CG, et al. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/82\">",
"      Scott TF, Hess D, Brillman J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994; 154:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/83\">",
"      Galindo-Rodr&iacute;guez G, Avi&ntilde;a-Zubieta JA, Pizarro S, et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 1999; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/84\">",
"      Rosenbaum JT, Simpson J, Neuwelt CM. Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 1997; 81:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/85\">",
"      Peponis V, Kyttaris VC, Tyradellis C, et al. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus 2006; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/86\">",
"      Sivaraj RR, Durrani OM, Denniston AK, et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/87\">",
"      Jabs DA, Fine SL, Hochberg MC, et al. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol 1986; 104:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/88\">",
"      Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 1988; 31:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/89\">",
"      Cao X, Bishop RJ, Forooghian F, et al. Autoimmune retinopathy in systemic lupus erythematosus: histopathologic features. Open Ophthalmol J 2009; 3:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/90\">",
"      Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 1995; 102:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/91\">",
"      Smith RJ, Maloney RK. Laser in situ keratomileusis in patients with autoimmune diseases. J Cataract Refract Surg 2006; 32:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/92\">",
"      Cua IY, Pepose JS. Late corneal scarring after photorefractive keratectomy concurrent with development of systemic lupus erythematosus. J Refract Surg 2002; 18:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/93\">",
"      Neumann R, Foster CS. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Retina 1995; 15:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/94\">",
"      Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998; 25:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/95\">",
"      D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/96\">",
"      Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/97\">",
"      Boumpas DT, Patronas NJ, Dalakas MC, et al. Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol 1990; 17:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/98\">",
"      Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/99\">",
"      Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 1992; 19:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/100\">",
"      Mak A, Chan BP, Yeh IB, et al. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology (Oxford) 2008; 47:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/101\">",
"      Levine SR, Langer SL, Albers JW, Welch KM. Sneddon's syndrome: an antiphospholipid antibody syndrome? Neurology 1988; 38:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/102\">",
"      Franc&egrave;s C, Papo T, Wechsler B, et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999; 78:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/103\">",
"      Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006; :CD002265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/104\">",
"      Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/105\">",
"      Ramos PC, Mendez MJ, Ames PR, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/106\">",
"      Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/107\">",
"      Tomietto P, D'Agostini S, Annese V, et al. Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol 2007; 34:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/108\">",
"      Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/109\">",
"      Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/110\">",
"      Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/11/33978/abstract/111\">",
"      Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000; 356:701.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4665 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-113.53.254.124-74B16A17D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33978=[""].join("\n");
var outline_f33_11_33978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27245977\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14540273\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14539089\">",
"      Secondary factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMMON CLINICAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cognitive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stroke syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14539199\">",
"      Psychiatric aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UNCOMMON NEUROLOGIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Movement disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cranial neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Eye involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Transverse myelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      USE OF MORE AGGRESSIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27245977\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4665|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/9/22687\" title=\"diagnostic image 1\">",
"      Lupus sclerosis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4665|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/42/13999\" title=\"picture 1A\">",
"      Cotton wool spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/35/43582\" title=\"picture 1B\">",
"      Retinal disease in SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/40/6796\" title=\"table 1\">",
"      ACR neuropsychiatric SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/40/18061\" title=\"table 2\">",
"      Sx neuropsychiatric lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/44/22220\" title=\"table 3\">",
"      Causes neuropsychiatric lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/58/41899\" title=\"table 4\">",
"      Common headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/30/18925\" title=\"table 5\">",
"      Ddx of aseptic meningitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5816?source=related_link\">",
"      Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=related_link\">",
"      Huntington disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_11_33979="Diagnosis of malabsorption";
var content_f33_11_33979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Practical advice in the diagnosis of malabsorption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Stools may appear normal even when laden with excess fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Patients with carbohydrate malabsorption may have watery diarrhea and complain of excess flatus and abdominal distension. Symptoms typically occur within 90 minutes of carbohydrate ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Abdominal pain is unusual in malabsorption except in the case of chronic pancreatitis, Crohn's disease, or pseudo-obstruction (eg, scleroderma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Patients with celiac disease often have a childhood history of ill health, and a positive family history of gluten sensitivity or Crohn's disease. A subtle presentation, such as anemia, is commonly the sole initial indication of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. The prevalence of celiac disease in patients with type 1 diabetes mellitus is higher than the general population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Always ask about previous surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Always ask about a history of recurrent peptic ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Do a careful physical examination looking for signs of nutrient malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Do not forget to ask about alcohol consumption. It usually takes 10 to 20 years for severe pancreatic insufficiency to develop in alcoholics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. A history of oil drops separated from the main stool mass, becoming whitish and firm after cooling (non-hydrolyzed triglycerides), strongly points toward pancreatic insufficiency as the cause",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33979=[""].join("\n");
var outline_f33_11_33979=null;
var title_f33_11_33980="Review of symptoms in gyn";
var content_f33_11_33980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Review of symptoms in gynecology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal Vaginal Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant increase or decrease in menstrual flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermenstrual or postcoital bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vulvovaginal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Presence of vaginal discharge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Odor, color, itching, burning, relationship to menses or intercourse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal dryness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar or vaginal pain with intercourse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar lesions, pain, infections, itching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pelvic pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time of onset: acute or chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensity and degree of debilitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relationship to menstrual cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relationship to eating, bowel, or bladder function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relationship to sexual or physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated symptoms, such as nausea or diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of analgesics or hormonal therapy and their effectiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        History of recurrent urinary tract infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Relationship to sexual activity or diaphragm use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use of suppressive antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysuria, urgency or urinary frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty voiding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary incontinence or leakage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pelvic relaxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sense of vaginal pressure or that something is \"falling out\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty with penetration during intercourse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Difficulty with voiding or defecating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Need to \"splint\", or apply vaginal pressure with above activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incontinence of urine, stool, flatus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33980=[""].join("\n");
var outline_f33_11_33980=null;
var title_f33_11_33981="Mgmt pre-exist conditions in ECT";
var content_f33_11_33981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic stenosis",
"       </td>",
"       <td>",
"        Echocardiography should be performed to assess severity if not done within the past year or if there is a change in symptoms. If stenosis is&nbsp;severe, then consult cardiologist before proceeding with ECT.",
"       </td>",
"       <td>",
"        Limited data suggest that ECT is safe with the use of short-acting intravenous beta-blockers to minimize procedure-related hypertension and tachycardia.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma or chronic obstructive pulmonary disease",
"       </td>",
"       <td>",
"        Discontinue theophylline by tapering the dose, if possible. Continue outpatient regimen of bronchodilators and inhaled glucocorticoids. Provide standard treatment during an asthma exacerbation (inhaled beta-agonists and, if necessary, glucocorticoids, before proceeding with ECT).",
"       </td>",
"       <td>",
"        Theophylline increases the risk of status epilepticus after ECT.",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation",
"       </td>",
"       <td>",
"        Continue outpatient medications for control of heart rate. Control heart rate with calcium-channel blockers if needed. Manage anticoagulation as described below.",
"       </td>",
"       <td>",
"        ECT appears to be safe in patients with atrial fibrillation. Patients may have conversion to and from sinus rhythm during ECT. The effect of spontaneous rate conversion on embolization rates is unknown.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery disease (stable)",
"       </td>",
"       <td>",
"        Continue medications such as aspirin, statins, antihypertensive agents, and antianginal medications, including nitrates for chronic cardiac conditions. Continue aspirin and clopidogrel in patients with coronary stents.",
"       </td>",
"       <td>",
"        Discontinuation of long-term cardiac medications on the morning of the procedure increases the risk of cardiac ischemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        Measure blood glucose levels before and after ECT treatment.&nbsp;If breakfast is likely only delayed, patients may delay taking their usual morning insulin until after ECT and before eating. If ECT happens later in the morning, where breakfast and lunch are likely to be missed, then give one-half the usual total morning dose as intermediate-acting insulin. Withhold oral agents and short-acting insulin until patient can eat.&nbsp;Perform ECT early in the morning if possible.",
"       </td>",
"       <td>",
"        The effect of ECT on blood glucose is unpredictable because of changes in diet, appetite, and energy level that may result from ECT. Individual ECT treatments raise blood glucose levels in patients with diabetes to the same degree as in patients without diabetes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension (poorly-controlled)",
"       </td>",
"       <td>",
"        Start or intensify antihypertensive medications; delay ECT until blood pressure is &lt;140/90 mmHg. Avoid beta-blockers.",
"       </td>",
"       <td rowspan=\"2\">",
"        Blood pressure increases during the postictal phase of ECT. Beta-blockers may shorten the seizure duration and reduce the efficacy of ECT.",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension (well-controlled)",
"       </td>",
"       <td>",
"        Continue usual antihypertensive medication(s).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Implantable cardioverter-defibrillator (ICD)",
"       </td>",
"       <td>",
"        Turn off detection mode of ICD during ECT. Perform continuous electrocardiographic monitoring throughout treatment. Place resuscitative equipment by the patient's bedside in the event that external defibrillation is necessary. Make sure that ICD has been interrogated routinely.",
"       </td>",
"       <td>",
"        ECT appears to be safe in patients with an ICD.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Implanted pacemaker",
"       </td>",
"       <td>",
"        A magnet should be available at the patient's bedside in the event that electrical interference leads to pacemaker inhibition and bradycardia.",
"       </td>",
"       <td>",
"        In rare cases, postprocedural supraventricular tachycardia can occur.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for long-term anticoagulation",
"       </td>",
"       <td>",
"        Continue anticoagulation to maintain an international normalized ratio of up to 3.5, unless there is an increased risk of intracranial hemorrhage (eg, intracranial mass or aneurysm).",
"       </td>",
"       <td>",
"        ECT appears to be safe in patients who require long-term anticoagulation.",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td>",
"        The informed-consent and risk-stratification process should include an obstetrician and an anesthesiologist. In addition to standard monitoring of the patient, noninvasive fetal monitoring should be used after 14-16 weeks. After 24 weeks, a nonstress test with a tocometer should be performed before and after treatments.",
"       </td>",
"       <td>",
"        Pregnancy would require modification of the anesthetic technique, positioning of the patient, and monitoring requirements.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sources:",
"     <ol>",
"      <li>",
"       Mueller PS, Barnes RD, Varghese R, et al. The safety of electroconvulsive therapy in patients with severe aortic stenosis. Mayo Clin Proc 2007; 82:1360.",
"      </li>",
"      <li>",
"       Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in patient receiving theophylline. J Clin Psychopharmacol 1988; 8:153.",
"      </li>",
"      <li>",
"       Rumi DO, Solimene MC, Takada JY, et al. Electrocardiographic and blood pressure alterations during electroconvulsive therapy in young adults. Arg Bras Cardiol 2002; 79:149.",
"      </li>",
"      <li>",
"       Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG. Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2004; 27:1257.",
"      </li>",
"      <li>",
"       Mehta V, Meuller PS, Gonzalez-Arriaza HL, et al. Safety of electroconvulsive therapy in patients receiving long-term warfarin therapy. Mayo Clin Proc 2004; 79:1396.",
"      </li>",
"     </ol>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33981=[""].join("\n");
var outline_f33_11_33981=null;
var title_f33_11_33982="Algorithm for managing PPROM";
var content_f33_11_33982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of patients with PPROM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 531px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Expectant management includes prophylactic antibiotics, corticosteroids (if fetal pulmonary immaturity), a 48 hour course of tocolytics to administer corticosteroids in patients with preterm labor and suspected pulmonary immaturity, and surveillance for maternal infection and fetal compromise. With rare exceptions, most patients will be delivered by 36 weeks of gestation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33982=[""].join("\n");
var outline_f33_11_33982=null;
var title_f33_11_33983="Jefferson C1 arch fracture open mouth xray";
var content_f33_11_33983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C1 arch fractures: Jefferson fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This odontoid or open-mouth view shows a Jefferson fracture. Note the step-off of the lateral masses (white arrow), which normally are in alignment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_11_33983=[""].join("\n");
var outline_f33_11_33983=null;
